Our experience

Нour specialists have considerable experience in all common nosologies, and also have special competence in conducting research of early phases. Use the filter to select the categories of research and services you are interested in.

Services






Year







INNCodeАТСServicesYear
Gemcitabine L01BC Pyrimidine Analogues Marketing Authorization 2010-2012
Levofloxacin J01MA Fluoroquinolones Marketing Authorization 2010-2012
Temozolomide L01AX Other Alkylating Agents Marketing Authorization 2010-2012
Aminosalicylic acid J04AA Aminosalicylic Acid and Derivatives Marketing Authorization 2010-2012
Amoxicillin + Clavulanic acid A07EC Aminosalicylic Acid and Similar Agents Marketing Authorization 2010-2012
Bisoprolol C07AB Beta Blocking Agents, Selective Marketing Authorization 2010-2012
Capreomycin J04AB Antibiotics Marketing Authorization 2010-2012
Cycloserine J04A Drugs For Treatment Of Tuberculosis Marketing Authorization 2010-2012
Diclofenac M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids Marketing Authorization 2010-2012
Drotaverine A03AD Papaverine and Derivatives Marketing Authorization 2010-2012
Epirubicin L01DB Anthracyclines and Related Substances Marketing Authorization 2010-2012
Hydrochlorothiazide + Losartan C09DA Angiotensin II Antagonists and Diuretics Marketing Authorization 2010-2012
Indapamide C03BA Sulfonamides, Plain Marketing Authorization 2010-2012
Ketorolac M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids Marketing Authorization 2010-2012
Levofloxacin J01MA Fluoroquinolones Marketing Authorization 2010-2012
Meropenem J01DH Carbapenems Marketing Authorization 2010-2012
Metamizole sodium + Pitofenone + Fenpiverinium bromide N02B Other Analgesics and Antipyretics Marketing Authorization 2010-2012
Nebivolol C07AB Beta Blocking Agents, Selective Marketing Authorization 2010-2012
Ornidazole J01XD Imidazole Derivatives Marketing Authorization 2010-2012
Rabeprazole A02BC Proton Pump Inhibitors Marketing Authorization 2010-2012
Anastrozole L02BG Enzyme Inhibitors Marketing Authorization 2010-2012
Bisoprolol C07AB Beta Blocking Agents, Selective Marketing Authorization 2010-2012
Clarithromycin J01FA Macrolides Marketing Authorization 2010-2012
Glucosamine + Chondroitin sulfate Potassium Adipate + Vitamin E M09AX Other Drugs For Disord. Of The Musc.-Skeletal Syst Marketing Authorization 2010-2012
Isoniazid + Pyrazinamide + Rifampicin J04AM Comb. Of Drugs For Treatment Of Tuberculosis Marketing Authorization 2010-2012
Letrozole L02BG Enzyme Inhibitors Marketing Authorization 2010-2012
Levetiracetam N03AX Other Antiepileptics Marketing Authorization 2010-2012
Moxifloxacin J01MA Fluoroquinolones Marketing Authorization 2010-2012
Mycophenolate mofetil L04AA Selective Immunosuppressive Agents Marketing Authorization 2010-2012
Nebivolol C07AB Beta Blocking Agents, Selective Marketing Authorization 2010-2012
Paracetamol N02B Other Analgesics and Antipyretics Marketing Authorization 2010-2012
Piperacillin + Tazobactam J01CR Piperacillin and Enzyme Inhibitor Marketing Authorization 2010-2012
Rebamipide A02BX Other Drugs For Treatment Of Peptic Ulcer Marketing Authorization 2010-2012
Tacrolimus L04AD Calcineurin inhibitors Marketing Authorization 2010-2012
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Marketing Authorization 2010-2012
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Bioequivalence CT 2010-2012
Aminosalicylic acid J04AA Aminosalicylic Acid and Derivatives Marketing Authorization 2013-2015
Citalopram N06AB Serotonin Reuptake Inhibitors Selective Marketing Authorization 2013-2015
Clopidogrel B01AC Platelet Aggregation Inhibitors Excl. Heparin Marketing Authorization 2013-2015
Cycloserine J04A Drugs For Treatment Of Tuberculosis Bioequivalence CT 2013-2015
Cycloserine + Pyridoxine J04A Drugs For Treatment Of Tuberculosis Bioequivalence CT 2013-2015
Cyproterone + Ethinylestradiol G03HB Antiandrogens and Estrogens Marketing Authorization 2013-2015
Darunavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2013-2015
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Bioequivalence CT 2013-2015
Gabapentin N03AX Other Antiepileptics Marketing Authorization 2013-2015
Heparin B01AB Heparin Group Marketing Authorization 2013-2015
Ketorolac M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids Marketing Authorization 2013-2015
Lamivudine J05AF Nucleoside reverse transcriptase inhibitors Marketing Authorization 2013-2015
Lamivudine J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2013-2015
Levofloxacin J01MA Fluoroquinolones Bioequivalence CT 2013-2015
Moxifloxacin J01MA Fluoroquinolones Bioequivalence CT 2013-2015
Nimesulide M01AX Other Antiinfl./Antirheumatic Agents, Non-Steroids Marketing Authorization 2013-2015
Sildenafil G04BE Drugs used in erectile dysfunction Bioequivalence CT 2013-2015
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Marketing Authorization 2013-2015
Topiramate N03AX Other Antiepileptics Marketing Authorization 2013-2015
Urofollitropin G03GA Gonadotrophins Marketing Authorization 2013-2015
Zidovudine + Lamivudine J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2013-2015
Abacavir J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2013-2015
Aminosalicylic acid J04AA Aminosalicylic Acid and Derivatives Marketing Authorization 2013-2015
Atracurium besilate M03AC Other Quaternary Ammonium Compounds Marketing Authorization 2013-2015
Darunavir J05AE HIV-proteinase inhibitors Marketing Authorization 2013-2015
Docetaxel L01CD Taxanes Marketing Authorization 2013-2015
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Marketing Authorization 2013-2015
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Bioequivalence CT 2013-2015
Famciclovir J05AB Nucleosides and nucleotides Bioequivalence CT 2013-2015
Imatinib L01XE Ингибиторы протеинкиназы Marketing Authorization 2013-2015
Imipenem + Cilastatin J01DH Carbapenems Marketing Authorization 2013-2015
Lamivudine + Zidovudine J05AR Antivirals for treatment of HIV infections, combination Marketing Authorization 2013-2015
Levocetirizine R06AE Piperazine Derivatives Bioequivalence CT 2013-2015
Levofloxacin J01MA Fluoroquinolones Marketing Authorization 2013-2015
Menotropins G03GA Gonadotrophins Marketing Authorization 2013-2015
Meropenem J01DH Carbapenems Marketing Authorization 2013-2015
Mesalazine A07EC Aminosalicylic Acid and Similar Agents Marketing Authorization 2013-2015
Moxifloxacin J01MA Fluoroquinolones Marketing Authorization 2013-2015
Moxifloxacin J01MA Fluoroquinolones Phase III CT 2013-2015
Natural phospholipids R07AA Lung Surfactants Marketing Authorization 2013-2015
Ofloxacin J01MA Fluoroquinolones Marketing Authorization 2013-2015
Paracetamol N02B Other Analgesics and Antipyretics Phase III CT 2013-2015
Peginterferon L03AB Interferons Phase III CT 2013-2015
Rabeprazole A02BC Proton Pump Inhibitors Bioequivalence CT 2013-2015
Sulodexide B01AB Heparin Group Phase III CT 2013-2015
Teicoplanin J01XA Glycopeptide Antibacterials Phase III CT 2013-2015
Terizidone + Pyridoxine J04AK Other Drugs For Treatment Of Tuberculosis Bioequivalence CT 2013-2015
Tobramycin J01GB Other Aminoglycosides Phase III CT 2013-2015
Torasemide C03CA Sulfonamides, Plain Bioequivalence CT 2013-2015
Abacavir + Lamivudine J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2013-2015
Aminosalicylic acid J04AA Aminosalicylic Acid and Derivatives Bioequivalence CT 2013-2015
Amoxicillin + Clavulanic acid A07EC Aminosalicylic Acid and Similar Agents Bioequivalence CT 2013-2015
Ceftriaxone + Sulbactam J01DD Third-generation cephalosporins Phase III CT 2013-2015
Celecoxib M01AH Coxibs Bioequivalence CT 2013-2015
Cinacalcet H05BX Other anti-parathyroid agents Bioequivalence CT 2013-2015
Ciprofloxacin J01MA Fluoroquinolones Marketing Authorization 2013-2015
Dienogest + Ethinylestradiol G03FA Progestogens and Estrogens, Fixed Combinations Bioequivalence CT 2013-2015
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Marketing Authorization 2013-2015
Efavirenz + Emtricitabine + Tenofovir J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2013-2015
Erlotinib L01XE Protein kinase inhibitors Marketing Authorization 2013-2015
Erlotinib L01XE Protein kinase inhibitors Bioequivalence CT 2013-2015
Famciclovir J05AB Nucleosides and nucleotides Marketing Authorization 2013-2015
Irbesartan C09CA Angiotensin II Antagonists, Plain Bioequivalence CT 2013-2015
Ivabradine C01EB Other Cardiac Preparations Marketing Authorization 2013-2015
Ivabradine C01EB Other Cardiac Preparations Bioequivalence CT 2013-2015
Latanoprost S01EE Prostaglandin analogues Phase III CT 2013-2015
Levofloxacin J01MA Fluoroquinolones Bioequivalence CT 2013-2015
Linezolid J01XX Other Antibacterials Marketing Authorization 2013-2015
Linezolid J01XX Other Antibacterials Bioequivalence CT 2013-2015
Linezolid J01XX Other Antibacterials Phase III CT 2013-2015
Losartan + Hydrochlorothiazide C09DA Angiotensin II Antagonists and Diuretics Marketing Authorization 2013-2015
Meropenem J01DH Carbapenems Marketing Authorization 2013-2015
Moxifloxacin J01MA Fluoroquinolones Marketing Authorization 2013-2015
Nevirapine J05AG Non-nucleoside reverse transcriptase inhibitors Marketing Authorization 2013-2015
Pimecrolimus D11AH Agents for atopic dermatitis, excluding corticosteroids Phase III CT 2013-2015
Pregabalin N03AX Other Antiepileptics Bioequivalence CT 2013-2015
Rabeprazole A02BC Proton Pump Inhibitors Marketing Authorization 2013-2015
Rabeprazole A02BC Proton Pump Inhibitors Bioequivalence CT 2013-2015
Stavudine J05AF Nucleoside reverse transcriptase inhibitors Marketing Authorization 2013-2015
Tenofovir + Emtricitabine J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2013-2015
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Bioequivalence CT 2013-2015
Terizidone + Pyridoxine J04AK Other Drugs For Treatment Of Tuberculosis Marketing Authorization 2013-2015
Timolol S01ED Beta Blocking Agents Marketing Authorization 2013-2015
Topiramate N03AX Other Antiepileptics Marketing Authorization 2013-2015
Travoprost S01EE Prostaglandin analogues Phase III CT 2013-2015
Valaciclovir J05AB Nucleosides and nucleotides Bioequivalence CT 2013-2015
Valganciclovir J05AB Nucleosides and nucleotides Bioequivalence CT 2013-2015
Valsartan C09CA Angiotensin II Antagonists, Plain Marketing Authorization 2013-2015
Cefepime J01DE Fourth-generation cephalosporins Marketing Authorization 2016-2018
Cinacalcet H05BX Other anti-parathyroid agents Marketing Authorization 2016-2018
Docetaxel L01CD Taxanes Phase III CT 2016-2018
Efavirenz + Emtricitabine + Tenofovir J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2016-2018
Entecavir J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2016-2018
Imatinib L01XE Ингибиторы протеинкиназы Marketing Authorization 2016-2018
Imatinib L01XE Ингибиторы протеинкиназы Bioequivalence CT 2016-2018
Irbesartan C09CA Angiotensin II Antagonists, Plain Marketing Authorization 2016-2018
Lenalidomide L04AX Other Immunosuppressive Agents Bioequivalence CT 2016-2018
Levocetirizine R06AE Piperazine Derivatives Marketing Authorization 2016-2018
Levofloxacin J01MA Fluoroquinolones Marketing Authorization 2016-2018
Levofloxacin J01MA Fluoroquinolones Bioequivalence CT 2016-2018
Linezolid J01XX Other Antibacterials Marketing Authorization 2016-2018
Moxifloxacin J01MA Fluoroquinolones Marketing Authorization 2016-2018
Nilotinib L01XE Protein kinase inhibitors Bioequivalence CT 2016-2018
Original drug B01AC Platelet Aggregation Inhibitors Excl. Phase III CT 2016-2018
Original drug J01DD Third-generation cephalosporins Phase III CT 2016-2018
Oseltamivir J05AH Combinations Of Antibacterials Bioequivalence CT 2016-2018
Peginterferon alfa-2b L03AB Interferons Marketing Authorization 2016-2018
Pregabalin N03AX Other Antiepileptics Marketing Authorization 2016-2018
Rosuvastatin C10AA HMG CoA Reductase Inhibitors Bioequivalence CT 2016-2018
Sildenafil G04BE Drugs used in erectile dysfunction Marketing Authorization 2016-2018
Sildenafil G04BE Drugs used in erectile dysfunction Bioequivalence CT 2016-2018
Sunitinib L01XE Protein kinase inhibitors Bioequivalence CT 2016-2018
Tacrolimus L04AD Calcineurin inhibitors Marketing Authorization 2016-2018
Temozolomide L01AX Other Alkylating Agents Bioequivalence CT 2016-2018
Tenofovir + Emtricitabine J05AR Antivirals for treatment of HIV infections, combination Marketing Authorization 2016-2018
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Marketing Authorization 2016-2018
Tramadol N02AX Other Opioids Marketing Authorization 2016-2018
Valganciclovir J05AB Nucleosides and nucleotides Marketing Authorization 2016-2018
Vancomycin J01XA Glycopeptide Antibacterials Marketing Authorization 2016-2018
Abacavir + Lamivudine J05AR Antivirals for treatment of HIV infections, combination Marketing Authorization 2016-2018
Abiraterone L02BX Other hormone antagonists and related agents Bioequivalence CT 2016-2018
Abiraterone L02BX Other hormone antagonists and related agents Marketing Authorization 2016-2018
Albendazole P02CA Benzimidazole Derivatives Bioequivalence CT 2016-2018
Aminosalicylic acid J04AA Aminosalicylic Acid and Derivatives Marketing Authorization 2016-2018
Bosentan C02KX Antihypertensives for pulmonary arterial hypertension Bioequivalence CT 2016-2018
Capecitabine L01BC Pyrimidine Analogues Bioequivalence CT 2016-2018
Celecoxib M01AH Coxibs Bioequivalence CT 2016-2018
Cisplatin L01XA Platinum Compounds Marketing Authorization 2016-2018
Clopidogrel B01AC Platelet Aggregation Inhibitors Excl. Heparin Marketing Authorization 2016-2018
Clopidogrel B01AC Platelet Aggregation Inhibitors Excl. Heparin Bioequivalence CT 2016-2018
Cycloserine J04A Drugs For Treatment Of Tuberculosis Bioequivalence CT 2016-2018
Darunavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2016-2018
Dorzolamide S01EC Carbonic Anhydrase Inhibitors Marketing Authorization 2016-2018
Entecavir J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2016-2018
Esomeprazole A02BC Proton Pump Inhibitors Bioequivalence CT 2016-2018
Etoricoxib M01AH Coxibs Bioequivalence CT 2016-2018
Etoricoxib M01AH Coxibs Marketing Authorization 2016-2018
Ferric (III) hydroxide sacharose complex B03AC Iron, Parenteral Preparations Marketing Authorization 2016-2018
Gefitinib L01XX Other Antineoplastic Agents Bioequivalence CT 2016-2018
Iohexol V08AB Watersol.,Nephrotropic, Low Osm. X-Ray Contr.Media Marketing Authorization 2016-2018
Lamivudine J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2016-2018
Meloxicam M01AC Oxicams Marketing Authorization 2016-2018
Montelukast R03DC Leukotriene receptor antagonists Marketing Authorization 2016-2018
Mycophenolic acid L04AA Selective Immunosuppressive Agents Bioequivalence CT 2016-2018
Nitrofurantoin J01XE Nitrofuran derivatives Marketing Authorization 2016-2018
Ofloxacin J01MA Fluoroquinolones Marketing Authorization 2016-2018
Original drug J01DD Third-generation cephalosporins Marketing Authorization 2016-2018
Paracetamol + Phenylephrine + Chlorphenamine maleate N02B Other Analgesics and Antipyretics Bioequivalence CT 2016-2018
Quetiapine N05AH Diazepines and oxazepines Bioequivalence CT 2016-2018
Ritonavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2016-2018
Rosuvastatin C10AA HMG CoA Reductase Inhibitors Marketing Authorization 2016-2018
Solifenacin G04BD Urinary Antispasmodics Bioequivalence CT 2016-2018
Sorafenib L01XE Protein kinase inhibitors Bioequivalence CT 2016-2018
Tenofovir J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2016-2018
Torasemide C03CA Sulfonamides, Plain Marketing Authorization 2016-2018
Tranexamic acid B02AA Amino Acids Marketing Authorization 2016-2018
Abacavir + Lamivudine + Zidovudine J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2016-2018
Amoxicillin + Clavulanic acid A07EC Aminosalicylic Acid and Similar Agents Marketing Authorization 2016-2018
Atazanavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2016-2018
Atazanavir J05AE HIV-proteinase inhibitors Marketing Authorization 2016-2018
Bendamustine L01AA Nitrogen Mustard Analogues Marketing Authorization 2016-2018
Cefepime + Sulbactam J01DE Fourth-generation cephalosporins Marketing Authorization 2016-2018
Ceftriaxone J01DD Third-generation cephalosporins Marketing Authorization 2016-2018
Chlorambucil L01AA Nitrogen Mustard Analogues Marketing Authorization 2016-2018
Cisplatin L01XA Platinum Compounds Marketing Authorization 2016-2018
Dasatinib L01XE Ингибиторы протеинкиназы Marketing Authorization 2016-2018
Doripenem J01DH Carbapenems Marketing Authorization 2016-2018
Doxorubicin L01DB Anthracyclines and Related Substances Marketing Authorization 2016-2018
Etoposide L01CB Podophyllotoxin Derivatives Marketing Authorization 2016-2018
Etoricoxib M01AH Coxibs Bioequivalence CT 2016-2018
Etoricoxib M01AH Coxibs Marketing Authorization 2016-2018
Fingolimod L04AA Selective Immunosuppressive Agents Bioequivalence CT 2016-2018
Fluorouracil L01BC Pyrimidine Analogues Marketing Authorization 2016-2018
Flutamide L02BB Anti-Androgens Marketing Authorization 2016-2018
Ganciclovir J05AB Nucleosides and nucleotides Marketing Authorization 2016-2018
Hydroxycarbamide L01XX Other Antineoplastic Agents Marketing Authorization 2016-2018
Ibrutinib L01XE Ингибиторы протеинкиназы Bioequivalence CT 2016-2018
Ketorolac trometamol M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids Phase III CT 2016-2018
Lapatinib L01XE Protein kinase inhibitors Bioequivalence CT 2016-2018
Lenalidomide L04AX Other Immunosuppressive Agents Marketing Authorization 2016-2018
Methotrexate L01BA Folic Acid Analogues Marketing Authorization 2016-2018
Nifuroxazide A07AX Other Intestinal Antiinfectives Marketing Authorization 2016-2018
Nilotinib L01XE Protein kinase inhibitors Marketing Authorization 2016-2018
Original drug B01AC Platelet Aggregation Inhibitors Excl. Marketing Authorization 2016-2018
Pantoprazole A02BC Proton Pump Inhibitors Bioequivalence CT 2016-2018
Pazopanib L01XE Protein kinase inhibitors Bioequivalence CT 2016-2018
Saquinavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2016-2018
Sofosbuvir J05AP Antivirals for treatment of HCV infections Bioequivalence CT 2016-2018
Tamoxifen L02BA Anti-Estrogens Marketing Authorization 2016-2018
Telmisartan C09CA Angiotensin II Antagonists, Plain Bioequivalence CT 2016-2018
Abiraterone L02BX Other hormone antagonists and related agents Marketing Authorization 2019-2020
Amlodipine C08CA Dihydropyridine Derivatives Marketing Authorization 2019-2020
Bleomycin L01DC Other Cytotoxic Antibiotics Marketing Authorization 2019-2020
Bromhexine + Guaifenesin + Salbutamol R05C Expectorants,Excl Combinations With Cough Suppr. Marketing Authorization 2019-2020
Carboplatin L01XA Platinum Compounds Marketing Authorization 2019-2020
Cyclophosphamide L01AA Nitrogen Mustard Analogues Marketing Authorization 2019-2020
Docetaxel L01CD Taxanes Marketing Authorization 2019-2020
Donepezil N06DA Cholinesterase inhibitors Marketing Authorization 2019-2020
Enoxaparin B01AB Heparin Group Marketing Authorization 2019-2020
Meropenem J01DH Carbapenems Marketing Authorization 2019-2020
Original drug G01BA Antibiotics and Corticosteroids Phase III CT 2019-2020
Original drug G01BA Antibiotics and Corticosteroids Marketing Authorization 2019-2020
Original drug J05AX Other Antivirals Marketing Authorization 2019-2020
Acetylcysteine + Ambroxol R05CB Mucolytics Phase III CT 2019-2021
Agomelatine N06AX Other Antidepressants Bioequivalence CT 2019-2021
Ambroxol + Salbutamol + Guaifenesin R05C Expectorants,Excl Combinations With Cough Suppr. Phase III CT 2019-2021
Cefepime + Sulbactam J01DE Fourth-generation cephalosporins Phase III CT 2019-2021
Ethylmethylhydroxypyridine succinate N07XX Other Nervous System Drugs Phase III CT 2019-2021
Olmesartan C09CA Angiotensin II Antagonists, Plain Bioequivalence CT 2019-2021
Lysocime + Pyridoxine R02AA Antiseptics Phase III CT 2019-2021
Pregabalin N03AX Other Antiepileptics Bioequivalence CT 2019-2021
Rosuvastatin C10AA HMG CoA Reductase Inhibitors Bioequivalence CT 2019-2021
Telmisartan C09CA Angiotensin II Antagonists, Plain Bioequivalence CT 2019-2021
Ursodeoxycholic acid A05AA Bile Acid Preparations Bioequivalence CT 2019-2021
Chlormadinone + Ethinyl Estradiol G03AA Progestogens and Estrogens, Fixed Combinations Bioequivalence CT 2019-2021
Ketolorac M01AB Acetic Acid Derivatives and Related Substances Phase III CT 2019-2021
Hydrocortisone acetate + Metronidazole + Natamycin + Chloramphenicol G01BA Antibiotics and Corticosteroids Phase III CT 2019-2021
Etravirin J05AG Ненуклеозиды - ингибиторы обратной транскриптазы Bioequivalence CT 2019-2021
Cinacalcet H05BX Other anti-parathyroid agents Bioequivalence CT 2019-2021
Sunitinib L01XE Protein kinase inhibitors Bioequivalence CT 2019-2021
Nitisinone A16AX Various Alimentary Tract and Metabolism Products Bioequivalence CT 2019-2021
Nilotinib L01XE Protein kinase inhibitors Bioequivalence CT 2019-2021
Lenalidomide L04AX Other Immunosuppressive Agents Bioequivalence CT 2019-2021
Desloratadine R06AX Other Antihistamines for systemic use Bioequivalence CT 2019-2021
Dasatinib L01XE Protein kinase inhibitors Bioequivalence CT 2019-2021
Acetylcysteine R05CB Mucolytics Bioequivalence CT 2019-2021
Gefitinib L01XX Other Antineoplastic Agents Bioequivalence CT 2019-2021
Chlorprothixen N05AF Thioxanthene Derivatives Bioequivalence CT 2019-2021
Etoricoxib M01AH Coxibs Bioequivalence CT 2019-2021
Vinorelbine L01CA Vinca alkaloids and analogues Marketing Authorization 2019-2021
Melatonin + Glycine N06BX Other Psychostimulants and Nootropics Phase III CT 2019-2021
Rabeprazole A02BC Proton Pump Inhibitors Bioequivalence CT 2019-2021
Trimebutine A03AA Synt Anticholin,Esters With Tertiary Amino Group Bioequivalence CT 2019-2021
Tolperisone M02AX Other Topical Products For Joint and Muscular Pain Bioequivalence CT 2019-2021
Mebeverine A03AA Synt Anticholin,Esters With Tertiary Amino Group Bioequivalence CT 2019-2021
Cefoperazone J01DD Third-generation cephalosporins Marketing Authorization 2019-2020
Cefoxitin J01DC Second-generation cephalosporins Marketing Authorization 2019-2020
Ketoanalogues of aminoacids V06DD Amino Acids, Incl Combinations With Polypeptides Marketing Authorization 2019-2020
Oseltamyvir J05AH Neuraminidase inhibitors Bringing dossier into the EEU complience 2019-2020
Paracetamol + Phenylephrine + Pheniramine + Ascorbic acid N02B Other Analgesics and Antipyretics Marketing Authorization 2019-2020
Paracetamol + Phenylephrine + Pheniramine + Caffeine N02B Other Analgesics and Antipyretics Marketing Authorization 2019-2020
Saquinavir J05AE HIV-proteinase inhibitors Marketing Authorization 2019-2020
Ademetionin A16AA Amino Acids and Derivatives Marketing Authorization 2019-2021
Ambroxol + Salbutamol + Guaifenesin R05C Expectorants,Excl Combinations With Cough Suppr. Marketing Authorization 2019-2021
Amoxicillin + Sulbactam J01CG Beta-Lactamase Inhibitors Marketing Authorization 2019-2021
Ampicillin + Sulbactam J01CR Comb Of Penicillins, Incl. Beta-Lactamase Inhib. Marketing Authorization 2019-2021
Amylmetacresol + Dichlorobenzyl alcohol R02AA Antiseptics Marketing Authorization 2019-2021
Anagrelide L01XX Other Antineoplastic Agents Marketing Authorization 2019-2021
Aripiprazole N05AX Other Antipsychotics Bioequivalence CT 2019-2021
Aripiprazole N05AX Other Antipsychotics Marketing Authorization 2019-2021
Aztreonam J01DF Monobactams Marketing Authorization 2019-2021
Caffeine + Paracetamol + Phenylephrine + Chlorphenamine N02B Other Analgesics and Antipyretics Marketing Authorization 2019-2021
Cefepime J01DE Fourth-generation cephalosporins Marketing Authorization 2019-2021
Cefoperazone + Sulbactam J01DD Third-generation cephalosporins Marketing Authorization 2019-2021
Ceftriaxone + Sulbactam J01DD Third-generation cephalosporins Marketing Authorization 2019-2021
Vildagliptin A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors Bioequivalence CT 2019-2021
Vildagliptin + Metformin A10BD Biguanides and Sulfonamides In Combination Bioequivalence CT 2019-2021
Clotrimazole D01A Antifungals for topical use Marketing Authorization 2019-2021
Cyproterone G03HA Antiandrogens, Plain Preparations Marketing Authorization 2019-2021
Cytisine N07BA Antismoking Agents Marketing Authorization 2019-2021
Dexmedetomidine N05CM Other Hypnotics and Sedatives Marketing Authorization 2019-2021
Dimetinden R06A Antihistamines for systemic use Marketing Authorization 2019-2021
Diosmin + Hesperidin C05CA Bioflavonoids Marketing Authorization 2019-2021
Docetaxel L01CD Taxanes Marketing Authorization 2019-2021
Domperidone A03FA Propulsives Marketing Authorization 2019-2021
Desogestrel + Ethinylestradiol G03AA Progestogens and Estrogens, Fixed Combinations Bioequivalence CT 2019-2021
Fluvoxamine N06AB Serotonin Reuptake Inhibitors Selective Marketing Authorization 2019-2021
Fosfomycin J01XX Other Antibacterials Marketing Authorization 2019-2021
Gemcitabine L01BC Pyrimidine Analogues Marketing Authorization 2019-2021
Ibuprofen M01AE Propionic Acid Derivatives Marketing Authorization 2019-2021
Ibuprofen + Paracetamol M01AE Propionic Acid Derivatives Marketing Authorization 2019-2021
Iodixanol V08A X-Ray Contrast Media, Iodinated Marketing Authorization 2019-2021
Irinotecan L01XX Ингибиторы протеинкиназы Marketing Authorization 2019-2021
Josamycin J01FA Macrolides Marketing Authorization 2019-2021
Lysocime + Pyridoxine R02AA Antiseptics Marketing Authorization 2019-2021
Metronidazole + Chlorhexidine A01AB Antiinfectives For Local Oral Treatment Marketing Authorization 2019-2021
Montelukast R03DC Leukotriene receptor antagonists Marketing Authorization 2019-2021
Naftifine D01A Antifungals for topical use Marketing Authorization 2019-2021
Natamycin A07AA Antibiotics Marketing Authorization 2019-2021
Nimesulide M01AX Other Antiinfl./Antirheumatic Agents, Non-Steroids Marketing Authorization 2019-2021
Olmesartan C09CA Angiotensin II Antagonists, Plain Marketing Authorization 2019-2021
Omeprazole A02BC Proton Pump Inhibitors Marketing Authorization 2019-2021
Ornidazole J01XD Imidazole Derivatives Marketing Authorization 2019-2021
Ornidazole + Ciprofloxacin J01RA Combinations Of Antibacterials Marketing Authorization 2019-2021
Pancreatin A09AA Enzyme Preparations Marketing Authorization 2019-2021
Phosphazide J05AF Nucleoside reverse transcriptase inhibitors Marketing Authorization 2019-2021
Telmisartan C09CA Angiotensin II Antagonists, Plain Marketing Authorization 2019-2021
Tigecycline J01AA Tetracyclines Marketing Authorization 2019-2021
Trastuzumab L01XC Monoclonal antibodies Marketing Authorization 2019-2021
Adalimumab L04AB Tumor necrosis factor alpha (TNFα) inhibitors Phase III CT 2019-2021
Donepezil N06DA Cholinesterase inhibitors Bioequivalence CT 2019-2021
Alglucosidase alfa A16AB Enzymes User testing of leaflet 2019-2021
Bortezomib L01XX Other Antineoplastic Agents User testing of leaflet 2019-2021
Oxaliplatin L01XA Platinum Compounds User testing of leaflet 2019-2021
Abacavir J05AF Nucleoside reverse transcriptase inhibitors User testing of leaflet 2019-2021
Levonorgestrel G03AC 3-Oxoandrosten (4) Derivatives User testing of leaflet 2019-2021
Cyproterone G03HA Antiandrogens, Plain Preparations User testing of leaflet 2019-2021
Cyproterone G03HA Antiandrogens, Plain Preparations User testing of leaflet 2019-2021
Decitabine L01BC Pyrimidine Analogues User testing of leaflet 2019-2021
Insulin glargine + Lixisenatide A10AE Insulins and analogues, long-acting User testing of leaflet 2019-2021
Darunavir J05AE HIV-proteinase inhibitors User testing of leaflet 2019-2021
Aceclofenac M01AB Acetic Acid Derivatives and Related Substances User testing of leaflet 2019-2021
Hydrochlorothiazidum + Telmisartan C09DA Angiotensin II Antagonists and Diuretics User testing of leaflet 2019-2021
Lenalidomide L04AX Other Immunosuppressive Agents User testing of leaflet 2019-2021
Etoricoxib M01AH Coxibs User testing of leaflet 2019-2021
Telmisartan + Amlodipin C09DB Angiotensin II receptor blockers (ARBs) and calcium channel blockers User testing of leaflet 2019-2021
Rosuvastatin + Valsartan C10BX HMG CoA reductase inhibitors, other combinations User testing of leaflet 2019-2021
Teriflunomide L04AA Selective Immunosuppressive Agents Bioequivalence CT 2019-2021
Sorafenib L01XE Protein kinase inhibitors Bioequivalence CT 2019-2021
Abacavir J05AF Nucleoside reverse transcriptase inhibitors Bringing dossier into the EEU complience 2019-2021
Bortezomib L01XX Ингибиторы протеинкиназы Bringing dossier into the EEU complience 2019-2021
Bromhexine + Guaifenesin + Salbutamol R05C Expectorants,Excl Combinations With Cough Suppr. Bringing dossier into the EEU complience 2019-2021
Darunavir J05AE HIV-proteinase inhibitors Bringing dossier into the EEU complience 2019-2021
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Bioequivalence CT 2019-2021
Etoricoxib M01AH Coxibs Bioequivalence CT 2019-2021
Adapalenum + Clindamycinum D01A Antifungals for topical use Bringing dossier into the EEU complience 2019-2021
Glucoseminyl muramildipeptide L03AX Other Immunostimulating Agents Bringing dossier into the EEU complience 2019-2021
Clotrimazole D01AC Imidazole Derivatives Bringing dossier into the EEU complience 2019-2021
Combined herb drug A01AD Other Agents For Local Oral Treatment Bioequivalence CT 2019-2021
Hydrochlorothiazidum + Telmisartan C09DA Angiotensin II Antagonists and Diuretics Bioequivalence CT 2019-2021
Indapamid + Perindopril + Rosuvastatin C10BX HMG CoA reductase inhibitors, other combinations Bioequivalence CT 2019-2021
Amlodipinum + Indapamidum + Perindoprilum C09BX Ингибиторы АПФ, другие комбинации Bioequivalence CT 2019-2021
Darunavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2019-2021
Etravirin J05AG Ненуклеозиды - ингибиторы обратной транскриптазы Bioequivalence CT 2019-2021
Abacavir J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2019-2021
Tenofovir J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2019-2021
Posaconazole J02AC ;Triazole Derivatives Bioequivalence CT 2019-2021
Teriflunomide L04AA Selective Immunosuppressive Agents Bioequivalence CT 2019-2021
Mycophenolic acid L04AA Selective Immunosuppressive Agents User testing of leaflet 2019-2021
Mycophenolate mofetil L04AA Selective Immunosuppressive Agents User testing of leaflet 2019-2021
Drugs for treatment of hyperkalemia and hyperphosphatemia V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia User testing of leaflet 2019-2021
Influenza Vaccines J07B Influenza Vaccines User testing of leaflet 2019-2021
Doxylamine R06AA Aminoalkyl Ethers User testing of leaflet 2019-2021
Algeldrate A02AX  Antacids User testing of leaflet 2019-2021
Fulvestrant L02BA Anti-Estrogens User testing of leaflet 2019-2021
Carvedilol C07AG Alpha and Beta Blocking Agents User testing of leaflet 2019-2021
Nifedipine C08CA Dihydropyridine Derivatives User testing of leaflet 2019-2021
Azithromycin J01FA Macrolides User testing of leaflet 2019-2021
Ciprofloxacin J01MA Fluoroquinolones User testing of leaflet 2019-2021
Lenvatinib L01XE Ингибиторы протеинкиназы User testing of leaflet 2019-2021
Nimesulide M01AX Other Antiinfl./Antirheumatic Agents, Non-Steroids User testing of leaflet 2019-2021
Clopidogrel B01AC Platelet Aggregation Inhibitors Excl. Heparin User testing of leaflet 2019-2021
Desloratadine R06AX Other Antihistamines for systemic use User testing of leaflet 2019-2021
immunoglobulin L04AA Selective Immunosuppressive Agents User testing of leaflet 2019-2021
Amiodarone C01BD Antiarrhythmics, Class III User testing of leaflet 2019-2021
Valproic acid N03AG Fatty Acid Derivatives User testing of leaflet 2019-2021
Poliomyelitis Vaccines J07BF Poliomyelitis Vaccines User testing of leaflet 2019-2021
Sorafenib L01XE Protein kinase inhibitors User testing of leaflet 2019-2021
Vardenafil G04BE Drugs used in erectile dysfunction User testing of leaflet 2019-2021
Regorafenib L01XE Protein kinase inhibitors User testing of leaflet 2019-2021
Telmisartan C09CA Angiotensin II Antagonists, Plain User testing of leaflet 2019-2021
Cemiplimab L01XC Monoclonal antibodies User testing of leaflet 2019-2021
Vericiguat C01DA Organic nitrates User testing of leaflet 2019-2021
Lenalidomide L04AX Other Immunosuppressive Agents User testing of leaflet 2019-2021
Combined herb drug A01AD Other Agents For Local Oral Treatment User testing of leaflet 2019-2021
Ibuprofen M01AE Propionic Acid Derivatives User testing of leaflet 2019-2021
Alectinib L01XE Protein kinase inhibitors User testing of leaflet 2019-2021
Rosuvastatin C10AA HMG CoA Reductase Inhibitors User testing of leaflet 2019-2021
Dabigatrani etexilas B01AA Vitamin K Antagonists User testing of leaflet 2019-2021
Faricimab L01XC Monoclonal antibodies User testing of leaflet 2019-2021
Finerenone C03DA Aldosterone Antagonists User testing of leaflet 2019-2021
Aducanumab N06DX Other anti-dementia drugs User testing of leaflet 2019-2021
Amlodipine C08CA Dihydropyridine Derivatives User testing of leaflet 2019-2021
Alirocumab C10AX Other Cholesterol and Triglyceride Reducers User testing of leaflet 2019-2021
Glycopyrronii bromidum + Indacaterolum H02AB Glucocorticoids User testing of leaflet 2019-2021
Agalsidase Alfa A16AB Enzymes User testing of leaflet 2019-2021
Viral Vaccines J07BX Other Viral Vaccines User testing of leaflet 2019-2021
Сitric acid + Potassium bicarbonate + Sodium citrate G04BC Urinary Concrement Solvents User testing of leaflet 2019-2021
Benzyldimethyl-myristoilamin-propylammonium D08AJ Quaternary Ammonium Compounds User testing of leaflet 2019-2021
Insulin glargine A10AE Insulins and analogues, long-acting User testing of leaflet 2019-2021
Ivacaftor R07AX Other Respiratory System Products User testing of leaflet 2019-2021
Clotrimazole D01A Antifungals for topical use User testing of leaflet 2019-2021
Abiraterone L02BX Other hormone antagonists and related agents User testing of leaflet 2019-2021
Sildenafil G04BE Drugs used in erectile dysfunction User testing of leaflet 2019-2021
Vemurafenib L01XE Protein kinase inhibitors User testing of leaflet 2019-2021
Thyme R05CA Expectorants User testing of leaflet 2019-2021
Salmeterol + Fluticasone R03AK Sympathomimetics in combination with corticosteroids or other drugs, excluding anticholinergics User testing of leaflet 2019-2021
Salbutamol sulfate R05CB Mucolytics User testing of leaflet 2019-2021
Metronidazole J01XD Imidazole Derivatives User testing of leaflet 2019-2021
Thiamine + Aescine C05CX Other Capillary Stabilizing Agents User testing of leaflet 2019-2021
Ticagrelor B01AC Platelet Aggregation Inhibitors Excl. Heparin User testing of leaflet 2019-2021
Levodopa N04BA Dopa and dopa derivatives User testing of leaflet 2019-2021
Adalimumab L04AB Tumor necrosis factor alpha (TNFα) inhibitors User testing of leaflet 2019-2021
Dapagliflozin A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors User testing of leaflet 2019-2021
Hederae folium R05CA Expectorants User testing of leaflet 2019-2021
Metronidazole A01AB Antiinfectives For Local Oral Treatment Bringing dossier into the EEU complience 2022-2024
Oxaliplatin L01XA Platinum Compounds Bringing dossier into the EEU complience 2022-2024
Interferon y L03AB Interferons Phase III CT 2022-2024
Ketoconazole + Pyrithione zinc D01A Antifungals for topical use Bringing dossier into the EEU complience 2022-2024
Desloratadine R06AX Other Antihistamines for systemic use Marketing Authorization 2022-2024
Tibolone G03CX Other estrogens Marketing Authorization 2022-2024
Acetylcysteine R05CB Mucolytics Marketing Authorization 2022-2024
Decitabine L01BC Pyrimidine Analogues Marketing Authorization 2022-2024
Imipenem + Cilastatin J01DH Carbapenems Marketing Authorization 2022-2024
Atosiban G02CX ;Gynecologicals, other Marketing Authorization 2022-2024
Iloprost B01AC Platelet Aggregation Inhibitors Excl. Marketing Authorization 2022-2024
Nimodipine C08CA Dihydropyridine Derivatives Marketing Authorization 2022-2024
Dexmedetomidine N05C ;Hypnotics and Sedatives Marketing Authorization 2022-2024
Teriflunomide L04AA Selective Immunosuppressive Agents Marketing Authorization 2022-2024
Nitisinone A16AX Various Alimentary Tract and Metabolism Products Marketing Authorization 2022-2024
Biapenem J01DD Third-generation cephalosporins Marketing Authorization 2022-2024
Paclitaxel L01CD Taxanes Marketing Authorization 2022-2024
Сolistimethate sodium J01XB Polymyxins Marketing Authorization 2022-2024
Cinacalcet H05BX Other anti-parathyroid agents Marketing Authorization 2022-2024
Gadodiamide V08CA Paramagnetic Contrast Media Marketing Authorization 2022-2024
Dantrolene M03CA Dantrolene and Derivatives Marketing Authorization 2022-2024
Ertapenem J01DH Carbapenems Marketing Authorization 2022-2024
Bromhexine + Guaifenesin + Salbutamol R05C Expectorants,Excl Combinations With Cough Suppr. Marketing Authorization 2022-2024
Vancomycin J01XA Glycopeptide Antibacterials Marketing Authorization 2022-2024
Tiepenem J01DH Carbapenems Marketing Authorization 2022-2024
Aminoacids for parenteral nutrition A16AA Amino Acids and Derivatives Bringing dossier into the EEU complience 2022-2024
Adapalenum + Clindamycinum D10AD Antifungals for topical use Bringing dossier into the EEU complience 2022-2024
Dabigatrani etexilas B01AA Vitamin K Antagonists Bioequivalence CT 2022-2024
Apixaban B01AF Other Antithrombotic Agents Bioequivalence CT 2022-2024
Dapagliflozin A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors Bioequivalence CT 2022-2024
Tilorone J05AX Other Antivirals Bioequivalence CT 2022-2024
Salmeterol + Fluticasone R03AK Sympathomimetics in combination with corticosteroids or other drugs, excluding anticholinergics User testing of leaflet 2022-2024
Sitagliptin A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors User testing of leaflet 2022-2024
Perampanel N03A Other Antiepileptics User testing of leaflet 2022-2024
Glycopyrronii bromidum H02AB Glucocorticoids User testing of leaflet 2022-2024
Baloxavir marboxil J05AX Other Antivirals User testing of leaflet 2022-2024
Plerixafor L03AX Other Immunostimulating Agents User testing of leaflet 2022-2024
Herbal drug R07AX Other Respiratory System Products User testing of leaflet 2022-2024
Cobimetinib L01XE Protein kinase inhibitors User testing of leaflet 2022-2024
Herbal drug A03AX Other Synthetic Anticholinergic Agents User testing of leaflet 2022-2024
Polyvitamine A11BA Multivitamins, Plain Bringing dossier into the EEU complience 2022-2024
Erlotinib L01XE Protein kinase inhibitors Marketing Authorization 2022-2024
Paliperidone N05AX ;Other Antipsychotics Marketing Authorization 2022-2024
Mometasone D07AC Corticosteroids, Potent (Group III) Marketing Authorization 2022-2024
Diclofenac M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids Bringing dossier into the EEU complience 2022-2024
Amylmetacresol + Dichlorobenzyl alcohol R02AA Antiseptics Bringing dossier into the EEU complience 2022-2024
Ademetionin A16AA Amino Acids and Derivatives Marketing Authorization 2022-2024
Piperacillin + Tazobactam J01CR Piperacillin and Enzyme Inhibitor Marketing Authorization 2022-2024
Cabazitaxel L01CD Taxanes Marketing Authorization 2022-2024
Cefoperazone + Sulbactam J01DD Third-generation cephalosporins Marketing Authorization 2022-2024
Rivaroxaban B01AF Direct factor Xa inhibitors Bioequivalence CT 2022-2024
Lapatinib L01XE Protein kinase inhibitors Bioequivalence CT 2022-2024
Telmisartan + Amlodipin C09DB Angiotensin II receptor blockers (ARBs) and calcium channel blockers Bioequivalence CT 2022-2024
Raltegravir J05AX Other Drugs For Treatment Of Tuberculosis Bioequivalence CT 2022-2024
Darunavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2022-2024
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Bioequivalence CT 2022-2024
Salmeterolum+ Fluticasonum R03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergicsAdrenergics in combination with corticosteroids or other drugs, excl. Anticholinergics User testing of leaflet 2022-2024
Sitagliptin A10BD Biguanides and Sulfonamides In Combination User testing of leaflet 2022-2024
Perampanel N03AX Other Antiepileptics User testing of leaflet 2022-2024
Glycopyrronium bromide R03AL Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
User testing of leaflet 2022-2024
Vildagliptin A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors User testing of leaflet 2022-2024
Vildagliptin + Metformin A10BD Biguanides and Sulfonamides In Combination User testing of leaflet 2022-2024
Fondaparinux sodium B01AX ;Other Antithrombotic Agents User testing of leaflet 2022-2024
Rivaroxaban B01AF Direct factor Xa inhibitors User testing of leaflet 2022-2024
Amlodipinum + Perindoprilum + Rosuvastatinum C10BX HMG CoA reductase inhibitors, other combinations User testing of leaflet 2022-2024
Dexketoprofen M01AE Propionic Acid Derivatives User testing of leaflet 2022-2024
Dimetinden R06A Antihistamines for systemic use User testing of leaflet 2022-2024
Dienogest G03FA Progestogens and Estrogens, Fixed Combinations User testing of leaflet 2022-2024
Mometasone furoate D07AC Corticosteroids, Potent (Group III) User testing of leaflet 2022-2024
Oseltamivir J05AH Combinations Of Antibacterials User testing of leaflet 2022-2024
Fludarabine L01BB Purine analogues User testing of leaflet 2022-2024
Drospirenonum+ Oestrogen G03AA Progestogens and estrogens, fixed combinations User testing of leaflet 2022-2024
Riociguat С02KX Antihypertensives for pulmonary arterial hypertension User testing of leaflet 2022-2024
Cemiplimab L01XC Monoclonal antibodies User testing of leaflet 2022-2024
Zinc sulfate A12CB ;Zincum User testing of leaflet 2022-2024
Desloratadine R06AX Other Antihistamines for systemic use User testing of leaflet 2022-2024
Metronidazole J01XD Imidazole Derivatives User testing of leaflet 2022-2024
Telmisartan C09CA Angiotensin II Antagonists, Plain User testing of leaflet 2022-2024
Ipidacrine N06DA Anticholinesterases User testing of leaflet 2022-2024
Insulin A10AB Insulins and analogues for injection, fast-acting User testing of leaflet 2022-2024
Torasemide C03CA Sulfonamides, Plain User testing of leaflet 2022-2024
Trimebutine A03AA Synt Anticholin,Esters With Tertiary Amino Group User testing of leaflet 2022-2024
Ibuprofen M01AE Propionic Acid Derivatives User testing of leaflet 2022-2024
Pyridoxine A11HA Other plain vitamin preparations User testing of leaflet 2022-2024
Cardui mariae fructus A05AX Other Drugs For Bile Therapy User testing of leaflet 2022-2024
Tacrolimus L04AD Calcineurin inhibitors User testing of leaflet 2022-2024
Cidofovir J05AB Nucleosides and nucleotides User testing of leaflet 2022-2024
Naproxen M01AE Propionic Acid Derivatives User testing of leaflet 2022-2024
Emicizumab B02BX Other systemic hemostatics User testing of leaflet 2022-2024
Salbutamol R03AC Selective beta-2-adrenoreceptor agonists User testing of leaflet 2022-2024
Ambroxol R05CB Mucolytics User testing of leaflet 2022-2024
Obinutuzumab L01FA ;CD20 (Clusters of Differentiation 20) inhibitors User testing of leaflet 2022-2024
Losartan C09DA Angiotensin II Antagonists and Diuretics User testing of leaflet 2022-2024
Faricimab L01XC Monoclonal antibodies User testing of leaflet 2022-2024
Ticagrelor B01AC Platelet Aggregation Inhibitors Excl. Heparin Bioequivalence CT 2022-2024
Vildagliptin A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors Bioequivalence CT 2022-2024
Areplivir J05AX Other Antivirals Bioequivalence CT 2022-2024
Ceftibuten J01DD Third generation cephalosporins Bioequivalence CT 2022-2024
Palbociclib L01EF Cyclin-dependent kinase (CDK) inhibitors Bioequivalence CT 2022-2024
Emtricitabine J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2022-2024
Amlodipinum + Indapamidum + Perindoprilum C09BX Ингибиторы АПФ, другие комбинации Marketing Authorization 2022-2024
Hydrochlorothiazidum + Telmisartan C09DA Angiotensin II Antagonists and Diuretics Marketing Authorization 2022-2024
Dabigatrani etexilas B01AA Vitamin K Antagonists Marketing Authorization 2022-2024
Amoxicillin + Sulbactam J01CG Beta-Lactamase Inhibitors Marketing Authorization 2022-2024
Ampicillin + Sulbactam J01CR Comb Of Penicillins, Incl. Beta-Lactamase Inhib. Marketing Authorization 2022-2024
Sulbactam J01DD Third-generation cephalosporins Marketing Authorization 2022-2024
Lansoprazole A02BD Other Drugs For Treatment Of Peptic Ulcer Marketing Authorization 2022-2024
Omeprazole A02BC Proton Pump Inhibitors Marketing Authorization 2022-2024
Rabeprazole A02BC Proton Pump Inhibitors Marketing Authorization 2022-2024
Pantoprazole A02BC Proton Pump Inhibitors Marketing Authorization 2022-2024
Tigecycline J01AA Tetracyclines Marketing Authorization 2022-2024
Esomeprazole A02BC Proton Pump Inhibitors Marketing Authorization 2022-2024
Micafungin J02AX Other Antimycotics for systemic use Marketing Authorization 2022-2024
Fondaparinux sodium B01AX ;Other Antithrombotic Agents Marketing Authorization 2022-2024
Cefepime + Sulbactam J01DE Fourth-generation cephalosporins Marketing Authorization 2022-2024
Fat Emulsions For Parenteral Nutrition B05BA Solutions For Parenteral Nutrition Marketing Authorization 2022-2024
Olmesartan + Amlodipine + Hydrochlorothiazide C09DB Angiotensin II receptor blockers (ARBs) and calcium channel blockers Marketing Authorization 2022-2024
Gemcitabine L01BC Pyrimidine Analogues Marketing Authorization 2022-2024
Polyvitamine A11BA Multivitamins, Plain Marketing Authorization 2022-2024
Vancomycin J01XA Glycopeptide Antibacterials Marketing Authorization 2022-2024
Sodium glycerophosphate B05XA Electrolyte solutions Marketing Authorization 2022-2024
Salbutamol R03AC Selective beta-2-adrenoreceptor agonists Marketing Authorization 2022-2024
Carfilzomib L01XG Proteasome inhibitors Marketing Authorization 2022-2024
Doripenem J01DH Carbapenems Marketing Authorization 2022-2024
Tadalafil G04BE Drugs used in erectile dysfunction Marketing Authorization 2022-2024
Caffeine + Paracetamol + Phenylephrine + Chlorphenamine N02B Other Analgesics and Antipyretics Marketing Authorization 2022-2024
Fedratinib L01EJ Lipid kinase inhibitors Marketing Authorization 2022-2024
Azacitidine L01BC ;Pyrimidine Analogues Marketing Authorization 2022-2024
Deucravacitinib L04AA Selective Immunosuppressive Agents Marketing Authorization 2022-2024
Clotrimazole D01A Antifungals for topical use Bringing dossier into the EEU complience 2022-2024
Combined herb drug A01AD Other Agents For Local Oral Treatment Bringing dossier into the EEU complience 2022-2024
Beta-alanine
G02CX Gynecologicals, other Bringing dossier into the EEU complience 2022-2024
Bromhexine + Guaifenesin + Salbutamol R05C Expectorants,Excl Combinations With Cough Suppr. Bringing dossier into the EEU complience 2022-2024
Clotrimazolum+Metronidazolum G01AF Imidazole Derivatives Bringing dossier into the EEU complience 2022-2024
Mometasone D07AC Corticosteroids, Potent (Group III) Bringing dossier into the EEU complience 2022-2024
Amolorfine D01AE ;Other Antifungals for topical use Bringing dossier into the EEU complience 2022-2024
Imiquimod D06BB Antivirals Bringing dossier into the EEU complience 2022-2024
Tibolone G03CX Other estrogens User testing of leaflet 2022-2024
Ceftriaxone + Sulbactam J01DD Third-generation cephalosporins User testing of leaflet 2022-2024
Valsartan + Amlodipine + Hydrochlorothiazide C09DX Angiotensin II antagonists, other combinations User testing of leaflet 2022-2024
Anifrolumab L01FX Прочие моноклональные антитела User testing of leaflet 2022-2024
Entrectinib L01XE Protein kinase inhibitors User testing of leaflet 2022-2024
Satralizumab L04AC Interleukin inhibitors User testing of leaflet 2022-2024
Melphalan L01AA Nitrogen Mustard Analogues User testing of leaflet 2022-2024
Viral Vaccines J07BX Other Viral Vaccines User testing of leaflet 2022-2024
Trientine A16AX Various Alimentary Tract and Metabolism Products User testing of leaflet 2022-2024
Ambroxol + Salbutamol + Guaifenesin R05C Expectorants,Excl Combinations With Cough Suppr. User testing of leaflet 2022-2024
Doxylamine hydrosuccinas R06AA Aminoalkyl Ethers User testing of leaflet 2022-2024
Glimepiride A10BB ;Sulfonamides, Urea Derivatives User testing of leaflet 2022-2024
Lozartan C09CA Angiotensin II Antagonists, Plain User testing of leaflet 2022-2024
Laronidase A16AB Enzymes User testing of leaflet 2022-2024
Vismodegib L01XJ Hedgehog pathway inhibitors User testing of leaflet 2022-2024
Salbutamol R03AC Selective beta-2-adrenoreceptor agonists User testing of leaflet 2022-2024
Sulbactam J01DD Third-generation cephalosporins User testing of leaflet 2022-2024
Busulfan L01AB Alkyl Sulphonates User testing of leaflet 2022-2024
Riamilovir J05AX Other Antivirals User testing of leaflet 2022-2024
Аmorolfine D01AE ;Other Antifungals for topical use User testing of leaflet 2022-2024
Valsartan C09CA Angiotensin II Antagonists, Plain User testing of leaflet 2022-2024
Valsartan + Hydrochlorothiazide C09DA Angiotensin II Antagonists and Diuretics User testing of leaflet 2022-2024
Levofloxacin J01MA Fluoroquinolones User testing of leaflet 2022-2024
Дименгидринат R06AX Other Antihistamines for systemic use User testing of leaflet 2022-2024
Moxonidine C02AC Imidazoline Receptor Agonists User testing of leaflet 2022-2024
Combined herb drug С04ВХ Other Urologicals User testing of leaflet 2022-2024
Fosfomycin J01XX Other Antibacterials User testing of leaflet 2022-2024
Pertuzumab L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors User testing of leaflet 2022-2024
Xylometazoline R01AA Sympathomimetics, Plain User testing of leaflet 2022-2024
Cefodizimum J01DD Third-generation cephalosporins User testing of leaflet 2022-2024
Trastuzumab emtansine L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors User testing of leaflet 2022-2024
Cefepime + Sulbactam J01DE Fourth-generation cephalosporins User testing of leaflet 2022-2024
Cetirizine R06AE Piperazine Derivatives User testing of leaflet 2022-2024
Alglucosidase alfa A16AB Enzymes User testing of leaflet 2022-2024
Valproic acid N03AG Fatty Acid Derivatives User testing of leaflet 2022-2024
Valproate sodium N03AG Fatty Acid Derivatives User testing of leaflet 2022-2024
Hydrochlorothiazide C03AA Thiazides, Plain User testing of leaflet 2022-2024
Finerenone C03DA Aldosterone Antagonists User testing of leaflet 2022-2024
Valsartan + Indapamide C09DA Angiotensin II Antagonists and Diuretics User testing of leaflet 2022-2024
Azithromycin J01FA Macrolides Bringing dossier into the EEU complience 2022-2024
Anagrelide L01XX Other Antineoplastic Agents Bringing dossier into the EEU complience 2022-2024
Аmorolfine D01AE ;Other Antifungals for topical use Bringing dossier into the EEU complience 2022-2024
Gadodiamide V08CA Paramagnetic Contrast Media Bringing dossier into the EEU complience 2022-2024
Gemcitabine L01BC Pyrimidine Analogues Bringing dossier into the EEU complience 2022-2024
Glucoseminyl muramildipeptide L03AX Other Immunostimulating Agents Bringing dossier into the EEU complience 2022-2024
Dantrolene M03CA Dantrolene and Derivatives Bringing dossier into the EEU complience 2022-2024
Dexmedetomidine N05CM Other Hypnotics and Sedatives Bringing dossier into the EEU complience 2022-2024
Dextromethorphanum+ Paracetamolum + Phenylephrinum+ Chlorphenaminum N02BE ;Anilides Bringing dossier into the EEU complience 2022-2024
Fat Emulsions For Parenteral Nutrition B05BA Solutions For Parenteral Nutrition Bringing dossier into the EEU complience 2022-2024
Ipratropium bromide + Fenoterol R03AL Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Bringing dossier into the EEU complience 2022-2024
Iodixanol V08AB Watersol.,Nephrotropic, Low Osm. X-Ray Contr.Media Bringing dossier into the EEU complience 2022-2024
Kalii acetas + Calcii acetas + Magnii acetas + Natrii acetas + Natrii chloridum B05BB Solutions Affecting The Electrolyte Balance Bringing dossier into the EEU complience 2022-2024
Carboplatin L01XA Platinum Compounds Bringing dossier into the EEU complience 2022-2024
Clotrimazolum G01AF Imidazole Derivatives Bringing dossier into the EEU complience 2022-2024
Immunostimulator L03AX Other Immunostimulating Agents Bringing dossier into the EEU complience 2022-2024
Meglumini acridоnacetas L03AX Other Immunostimulating Agents Bringing dossier into the EEU complience 2022-2024
Mometasone D07AC Corticosteroids, Potent (Group III) Bringing dossier into the EEU complience 2022-2024
Azelastinum + Mometasonum H02BX Corticosteroids for systemic use, Combinations Bringing dossier into the EEU complience 2022-2024
Nimesulide M01AX Other Antiinfl./Antirheumatic Agents, Non-Steroids Bringing dossier into the EEU complience 2022-2024
Temozolomide L01AX Other Alkylating Agents Bringing dossier into the EEU complience 2022-2024
Teriflunomide L04AA Selective Immunosuppressive Agents Bringing dossier into the EEU complience 2022-2024
Tigecycline J01AA Tetracyclines Bringing dossier into the EEU complience 2022-2024
Tizanidine M03BX Other Centrally Acting Agents Bringing dossier into the EEU complience 2022-2024
Famciclovir J05AB Nucleosides and nucleotides Bringing dossier into the EEU complience 2022-2024
Phosphazide J05AF Nucleoside reverse transcriptase inhibitors Bringing dossier into the EEU complience 2022-2024
Cefuroxime J01RA Combinations Of Antibacterials Bringing dossier into the EEU complience 2022-2024
Cinacalcet H05BX Other anti-parathyroid agents Bringing dossier into the EEU complience 2022-2024
Cytisine N07BA Antismoking Agents Bringing dossier into the EEU complience 2022-2024
Etoposide L01CB Podophyllotoxin Derivatives Bringing dossier into the EEU complience 2022-2024
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Bringing dossier into the EEU complience 2022-2024
Amlodipinum + Indapamidum + Perindoprilum C09BX Ингибиторы АПФ, другие комбинации Marketing Authorization 2022-2024
Telmisartan + Amlodipin C09DB Angiotensin II receptor blockers (ARBs) and calcium channel blockers Marketing Authorization 2022-2024
Аmorolfine D01AE ;Other Antifungals for topical use Marketing Authorization 2022-2024
Apixaban B01AF Other Antithrombotic Agents Marketing Authorization 2022-2024
Valaciclovir J05AB Nucleosides and nucleotides Marketing Authorization 2022-2024
Gadopentetic acid V08CA Paramagnetic Contrast Media Marketing Authorization 2022-2024
Geparin sodium C05BA Preparations With Heparin for topical use Marketing Authorization 2022-2024
Dimetindene + Phenylephrine R01AB Sympathomimetics,Combinations Excl Corticosteroids Marketing Authorization 2022-2024
Indapamid + Perindopril + Rosuvastatin C10BX HMG CoA reductase inhibitors, other combinations Marketing Authorization 2022-2024
Pazufloxacin J01MA Fluoroquinolones Marketing Authorization 2022-2024
Coffeinum + Paracetamolum + Phenylephrinum + Chlorphenaminum N02BE ;Anilides Marketing Authorization 2022-2024
Paricalcitol H05BX Other anti-parathyroid agents Marketing Authorization 2022-2024
Raltegravir J05AX Other Drugs For Treatment Of Tuberculosis Marketing Authorization 2022-2024
Teicoplanin J01XA Glycopeptide Antibacterials Marketing Authorization 2022-2024
Ursodeoxycholic acid A05AA Bile Acid Preparations Marketing Authorization 2022-2024
Cefaktiv J01DE Fourth-generation cephalosporins Marketing Authorization 2022-2024
Cefodizimum J01DD Third-generation cephalosporins Marketing Authorization 2022-2024
Ceftriaxone + Sulbactam J01DD Third-generation cephalosporins Marketing Authorization 2022-2024
Cefuroxime J01RA Combinations Of Antibacterials Marketing Authorization 2022-2024
Hydrochlorothiazidum + Telmisartan C09DA Angiotensin II Antagonists and Diuretics Bioequivalence CT 2022-2024
Amlodipinum + Perindoprilum + Rosuvastatinum C10BX HMG CoA reductase inhibitors, other combinations Bioequivalence CT 2022-2024
Amlodipinum + Indapamidum + Perindoprilum C09BX Ингибиторы АПФ, другие комбинации Bioequivalence CT 2022-2024
Diacerein M01AX Other Antiinfl./Antirheumatic Agents, Non-Steroids Bioequivalence CT 2022-2024
Diosmin + Hesperidin C05CA Bioflavonoids Bioequivalence CT 2022-2024
Nimesulide M01AX Other Antiinfl./Antirheumatic Agents, Non-Steroids Bioequivalence CT 2022-2024
Anastrozole L02BG Enzyme Inhibitors Bioequivalence CT 2022-2024
Axitinib L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors Bioequivalence CT 2022-2024
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Bioequivalence CT 2022-2024
Dolutegravir + Rilpivirine J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2022-2024
Abemaciclibum L01EF Cyclin-dependent kinase (CDK) inhibitors Bioequivalence CT 2022-2024
Glecaprevir + Pilbrentasvir J05AX Other Antivirals Bioequivalence CT 2022-2024
Grazoprevir + Elbasvir J05AP Antivirals for treatment of HCV infections Bioequivalence CT 2022-2024
Safinamid N04BD N04BD User testing of leaflet 2022-2024
Drotaverine A03AD Papaverine and Derivatives User testing of leaflet 2022-2024
Atorvastatin C10AA HMG CoA Reductase Inhibitors User testing of leaflet 2022-2024
Benzoyl peroxide + Сlindamycin D10AF Antiinfectives For Treatment Of Acne User testing of leaflet 2022-2024
Drospirenone + Ethinylestradiol G03AA Progestogens and estrogens, fixed combinations User testing of leaflet 2022-2024
Apixaban B01AF Other Antithrombotic Agents User testing of leaflet 2022-2024
Ticagrelor B01AC Platelet Aggregation Inhibitors Excl. Heparin User testing of leaflet 2022-2024
Gadopentetic acid V08CA Paramagnetic Contrast Media User testing of leaflet 2022-2024
Etoricoxib M01AH Coxibs User testing of leaflet 2022-2024
Gemcitabin L01BC Pyrimidine Analogues User testing of leaflet 2022-2024
Glucosamine + Ibuprofen + Chondroitin sulfate M01AE Propionic Acid Derivatives Bioequivalence CT 2022-2024
Apixaban B01AF Other Antithrombotic Agents Bioequivalence CT 2022-2024
Alfacalcidol + Calcium carbonate A11CC Vitamin D and analogues Bringing dossier into the EEU complience 2022-2024
Ambrisentan C02KX Antihypertensives for pulmonary arterial hypertension Bringing dossier into the EEU complience 2022-2024
Aminoacids for parenteral nutrition B05BA Solutions for parenteral nutrition Bringing dossier into the EEU complience 2022-2024
Aminoacids for parenteral nutrition + Other medicines [Fat emulsions + Dextrose + Multimineral] B05BA Solutions for parenteral nutrition Bringing dossier into the EEU complience 2022-2024
Amorolfine D01AE Other Antifungals For Topical Use Bringing dossier into the EEU complience 2022-2024
Anagrelide L01XX Other antineoplastic agents Bringing dossier into the EEU complience 2022-2024
Bromhexine + Guaifenesin + Salbutamol R05C EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS Bringing dossier into the EEU complience 2022-2024
Varicella Zoster Vaccines J07BK Varicella Zoster Vaccines Bringing dossier into the EEU complience 2022-2024
Measles, mumps, rubella, and varicella vaccine J07BD Measles Vaccines Bringing dossier into the EEU complience 2022-2024
Papillomavirus vaccines J07BM Papillomavirus vaccines Bringing dossier into the EEU complience 2022-2024
Water for injections V07AB Solvents and Diluting Agents,Incl Irrigat Solut Bringing dossier into the EEU complience 2022-2024
Gemcitabine L01BC Pyrimidine analogues Bringing dossier into the EEU complience 2022-2024
Glucoseminyl muramildipeptide L03A IMMUNOSTIMULANTS Bringing dossier into the EEU complience 2022-2024
Granisetron A04AA Serotonin (5HT3) antagonists Bringing dossier into the EEU complience 2022-2024
Dactinomycin L01DA Actinomycines Bringing dossier into the EEU complience 2022-2024
Dexmedetomidine N05CM Other hypnotics and sedatives Bringing dossier into the EEU complience 2022-2024
Dextromethorphan + Paracetamol + Phenylephrine + Chlorphenamine N07XX Anilides Bringing dossier into the EEU complience 2022-2024
Decitabine L01BC Pyrimidine analogues Bringing dossier into the EEU complience 2022-2024
Diclofenac + Orphenadrine M01AB Acetic acid derivatives and related substances Bringing dossier into the EEU complience 2022-2024
Dinutuximab beta L01FX Other monoclonal antibodies Bringing dossier into the EEU complience 2022-2024
Duloxetine N06AX Other antidepressants Bringing dossier into the EEU complience 2022-2024
Fat Emulsions B05BA Solutions for parenteral nutrition Bringing dossier into the EEU complience 2022-2024
Imipenem and cilastatin J01DH Carbapenems Bringing dossier into the EEU complience 2022-2024
Imiquimod D06BB Antivirals Bringing dossier into the EEU complience 2022-2024
Potassium acetate + Calcium acetate + Magnesium acetate + Sodium acetate + Sodium chloride B05BB Solutions affecting the electrolyte balance Bringing dossier into the EEU complience 2022-2024
Carboplatin L01XA Platinum compounds Bringing dossier into the EEU complience 2022-2024
Ketorolac M01AB Acetic acid derivatives and related substances Bringing dossier into the EEU complience 2022-2024
Ketoanalogues of aminoacids V06DD Amino Acids,Incl Combinations With Polypeptides Bringing dossier into the EEU complience 2022-2024
Caffeine + Paracetamol + Phenylephrine + Pheniramine N02BE Anilides Bringing dossier into the EEU complience 2022-2024
Lactulose A06AD Osmotically acting laxatives Bringing dossier into the EEU complience 2022-2024
Levofloxacin J01MA Fluoroquinolones Bringing dossier into the EEU complience 2022-2024
Levocetirizine R06AE Piperazine derivatives Bringing dossier into the EEU complience 2022-2024
Leflunomide L04AA Selective immunosuppressants Bringing dossier into the EEU complience 2022-2024
Bacteriolysas L03AX Other Immunostimulants Bringing dossier into the EEU complience 2022-2024
Meglumine acridonacetate L03AX Other Immunostimulating Agents Bringing dossier into the EEU complience 2022-2024
Meropenem J01DH Carbapenems Bringing dossier into the EEU complience 2022-2024
Mometasone D07AC Corticosteroids, potent (group III) Bringing dossier into the EEU complience 2022-2024
Mometasone + Azelastine R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Bringing dossier into the EEU complience 2022-2024
Nimesulide M01AX Other antiinflammatory and antirheumatic agents, non-steroids Bringing dossier into the EEU complience 2022-2024
Oxaliplatin L01XA Platinum compounds Bringing dossier into the EEU complience 2022-2024
Omeprazole A02BC Proton pump inhibitors Bringing dossier into the EEU complience 2022-2024
Paclitaxel L01CD Taxanes Bringing dossier into the EEU complience 2022-2024
Piperacillin + Tazobactam J01CR Combinations of penicillins, incl. beta-lactamase inhibitors Bringing dossier into the EEU complience 2022-2024
Multivitamins [parenteral injection] A11BA Multivitamins, plain Bringing dossier into the EEU complience 2022-2024
Polymyxin B A07AA Antibiotics Bringing dossier into the EEU complience 2022-2024
Peritoneal Dialytics B05D Peritoneal Dialytics Bringing dossier into the EEU complience 2022-2024
Rocuronium bromide M03AC Other quaternary ammonium compounds Bringing dossier into the EEU complience 2022-2024
Simoctocog alfa B02BD Blood Coagulation Factors Bringing dossier into the EEU complience 2022-2024
Natural peptides and cytokines peptide-protein complex L03 Immunomodulating Agents Bringing dossier into the EEU complience 2022-2024
Suprima-Broncho R05X OTHER COLD PREPARATIONS Bringing dossier into the EEU complience 2022-2024
Temozolomide L01AX Other alkylating agents Bringing dossier into the EEU complience 2022-2024
Tizanidine M03BX Other centrally acting agents Bringing dossier into the EEU complience 2022-2024
Coagulation Factor IX B02BD Blood Coagulation Factors Bringing dossier into the EEU complience 2022-2024
Furazidin J01XE Nitrofuran derivatives Bringing dossier into the EEU complience 2022-2024
Celecoxib L01XX Other antineoplastic agents Bringing dossier into the EEU complience 2022-2024
Cefoperazone+Sulbactam J01DD Third-generation cephalosporins Bringing dossier into the EEU complience 2022-2024
Ceftriaxone J01DD Third-generation cephalosporins Bringing dossier into the EEU complience 2022-2024
Cefuroxime J01DC Second-generation cephalosporins Bringing dossier into the EEU complience 2022-2024
Ciclosporin L04AD Calcineurin inhibitors Bringing dossier into the EEU complience 2022-2024
Cytisine N07BA Drugs used in nicotine dependence Bringing dossier into the EEU complience 2022-2024
Etoposide L01CB Podophyllotoxin derivatives Bringing dossier into the EEU complience 2022-2024
Patiromer V03AE Drugs For Treatment Of Hyperkalemia And Hyperphosphatemia User testing of leaflet 2022-2024
Rosuvastatin C10AA HMG CoA reductase inhibitors User testing of leaflet 2022-2024
Hydrochlorothiazide + losartan C09DA Angiotensin II Antagonists And Diuretics User testing of leaflet 2022-2024
Polatuzumab vedotin B01AC Platelet Aggregation Inhibitors Excl. Heparin User testing of leaflet 2022-2024
Tranexamic acid B02AA Аминокислоты User testing of leaflet 2022-2024
Insulin glargine A10AE Insulins And Analogues For Injection, Long-Acting User testing of leaflet 2022-2024
Anifrolumab L04AA Selective Immunosuppressants User testing of leaflet 2022-2024
Perindopril C09AA ACE Inhibitors, Plain User testing of leaflet 2022-2024
Ipratropium bromide + xylometazoline R01AB Sympathomimetics, combinations excl. Corticosteroids User testing of leaflet 2022-2024
Rivaroxaban B01AF01 Direct factor Xa inhibitors User testing of leaflet 2022-2024
Levonorgestrel G02BA Intrauterine Contraceptives User testing of leaflet 2022-2024
Amlodipine + perindopril C09BB ACE Inhibitors And Calcium Channel Blockers User testing of leaflet 2022-2024
Mometasone R01AD Corticosteroids User testing of leaflet 2022-2024
Dabigatran etexilate B01AE Direct Thrombin Inhibitors User testing of leaflet 2022-2024
Adapalene D10AD Retinoids for topical use in acne User testing of leaflet 2022-2024
Ademetionine A16AA Amino acids and derivatives User testing of leaflet 2022-2024
Acalabrutinib L01EL Bruton`s tyrosine kinase (BTK) inhibitors User testing of leaflet 2022-2024
Ambroxol R05CB Mucolytics User testing of leaflet 2022-2024
Amiodarone C01BD Antiarrhythmics, Class III User testing of leaflet 2022-2024
Valsartan, Amlodipine and Hydrochlorothiazide C09DX Angiotensin II antagonists, other combinations User testing of leaflet 2022-2024
Amlodipinum + Indapamidum + Perindoprili C09BX ACE inhibitors, other combinations User testing of leaflet 2022-2024
Telmisartan and Amlodipine C09DB Angiotensin II antagonists and calcium channel blockers User testing of leaflet 2022-2024
Amoxicillin+Clavulanic acid J01CR Amoxicillin and Enzyme Inhibitor User testing of leaflet 2022-2024
Amorolfine D01AE Other Antifungals for topical use User testing of leaflet 2022-2024
Asfotase alfa A16AB Enzymes User testing of leaflet 2022-2024
Atezolizumab L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors User testing of leaflet 2022-2024
Atorvastatin C10AA HMG CoA reductase inhibitors User testing of leaflet 2022-2024
Aceclofenac M01AB Acetic Acid Derivatives And Related Substances User testing of leaflet 2022-2024
Belimumab L04AA Selective Immunosuppressive Agents User testing of leaflet 2022-2024
Busulfan L01AB Alkyl sulfonates User testing of leaflet 2022-2024
Bacterial and Viral Vaccines, Combined J07CA Bacterial and Viral Vaccines, Combined User testing of leaflet 2022-2024
Valsartan C09CA Angiotensin II antagonists, plain User testing of leaflet 2022-2024
Valsartan+Hydrochlorothiazide C09DX Valsartan and diuretics User testing of leaflet 2022-2024
Valproic Acid N03AG Fatty acid derivatives User testing of leaflet 2022-2024
Vancomycin J01XA Glycopeptide antibacterials User testing of leaflet 2022-2024
Vilanterol, umeclidinium bromide and fluticasone furoate R03AL Adrenergics in combination with anticholinergics User testing of leaflet 2022-2024
Vildagliptin A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors User testing of leaflet 2022-2024
Metformin and vildagliptin A10BD Combinations Of Oral Blood Glucose Lowering Drugs User testing of leaflet 2022-2024
Gadopentetic acid V08CA Paramagnetic Contrast Media User testing of leaflet 2022-2024
Gemcitabine L01BC Pyrimidine analogues User testing of leaflet 2022-2024
Gestodene and Estrogen G03AA Progestogens and estrogens, fixed combinations User testing of leaflet 2022-2024
Dabigatran etexilate B01AE Direct thrombin inhibitors User testing of leaflet 2022-2024
Danicopan L04AJ Selective Immunosuppressive Agents User testing of leaflet 2022-2024
Dapagliflozin A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors User testing of leaflet 2022-2024
;Dexpanthenol D03AX Other cicatrizants User testing of leaflet 2022-2024
Dienogest + Ethinylestradiol G03AA Progestogens and estrogens, fixed combinations User testing of leaflet 2022-2024
Dimenhydrinate R06AA Aminoalkyl ethers User testing of leaflet 2022-2024
Dolutegravir and rilpivirin J05AR Antivirals for treatment of HIV infections, combinations User testing of leaflet 2022-2024
Drospirenone + Ethinylestradiol G03AA Progestogens and estrogens, fixed combinations User testing of leaflet 2022-2024
Ibuprofen, Combinations M01AE Propionic acid derivatives User testing of leaflet 2022-2024
Ivacaftor, tezacaftor and elexacaftor R07AX Other respiratory system products User testing of leaflet 2022-2024
Rosuvastatin, ­perindopril and ­indapamide C10BX HMG CoA reductase inhibitors, other combinations User testing of leaflet 2022-2024
Insulin glargine A10AE Insulins and analogues for injection, long-acting User testing of leaflet 2022-2024
Insulin glulisine A10AB Insulins and analogues for injection, fast-acting User testing of leaflet 2022-2024
Iohexol V08AB Watersoluble, nephrotropic, low osmolar X-ray contrast media User testing of leaflet 2022-2024
Cabazitaxel L01CD Taxanes User testing of leaflet 2022-2024
Capivasertib L01EX Other protein kinase inhibitors User testing of leaflet 2022-2024
Carboplatin L01XA Platinum compounds User testing of leaflet 2022-2024
Carfilzomib L01XG Proteasome inhibitors User testing of leaflet 2022-2024
Caspofungin J02AX Other antimycotics for systemic use User testing of leaflet 2022-2024
Clindamycin D10AF Antiinfectives for treatment of acne User testing of leaflet 2022-2024
Colistimethate sodium J01XB Polymyxins User testing of leaflet 2022-2024
Xylometazoline R01AA Sympathomimetics, plain User testing of leaflet 2022-2024
Lansoprazole A02BC Proton pump inhibitors User testing of leaflet 2022-2024
Latanoprost S01EE Prostaglandin Analogues User testing of leaflet 2022-2024
Levonorgestrel G03AC Progestogens User testing of leaflet 2022-2024
Levofloxacin J01MA Fluoroquinolones User testing of leaflet 2022-2024
Metoprolol C07AB Beta blocking agents, selective User testing of leaflet 2022-2024
Metronidazole D06BX Other chemotherapeutics User testing of leaflet 2022-2024
Moxifloxacin J01MA Fluoroquinolones User testing of leaflet 2022-2024
Mosunetuzumab L01FX Other monoclonal antibodies User testing of leaflet 2022-2024
Norelgestromin + ethinylestradiol G03AA Progestogens and estrogens, fixed combinations User testing of leaflet 2022-2024
Ocrelizumab L04AA Selective immunosuppressants User testing of leaflet 2022-2024
Olaparib L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors User testing of leaflet 2022-2024
Pazufloxacin J01MA Fluoroquinolones User testing of leaflet 2022-2024
Pantoprazole A02BC Proton pump inhibitors User testing of leaflet 2022-2024
Perampanel N03AX Other antiepileptics User testing of leaflet 2022-2024
Pertuzumab L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors User testing of leaflet 2022-2024
Pertuzumab and trastuzumab L01XY Combinations of antineoplastic agents User testing of leaflet 2022-2024
Piperacillin + Tazobactam J01CR Combinations of penicillins, incl. beta-lactamase inhibitors User testing of leaflet 2022-2024
Hederae folium R05CA Expectorants User testing of leaflet 2022-2024
Multivitamins, Plain A11BA Multivitamins, Plain User testing of leaflet 2022-2024
Ravulizumab L04AA Selective immunosuppressants User testing of leaflet 2022-2024
Rivaroxaban B01AF Direct factor Xa inhibitors User testing of leaflet 2022-2024
Rituximab L01FA CD20 (Clusters of Differentiation 20) inhibitors User testing of leaflet 2022-2024
Sevoflurane N01AB Halogenated hydrocarbons User testing of leaflet 2022-2024
Selumetinib L01EE Mitogen-activated protein kinase (MEK) inhibitors User testing of leaflet 2022-2024
Sulbactam J01CG Beta-lactamase inhibitors User testing of leaflet 2022-2024
Tezepelumab R03DX Other systemic drugs for obstructive airway diseases User testing of leaflet 2022-2024
Telmisartan C09CA Angiotensin II antagonists, plain User testing of leaflet 2022-2024
Testosterone G03BA 3-Oxoandrosten (4) Derivatives User testing of leaflet 2022-2024
Tetryzoline S01GA Sympathomimetics Used As Decongestants User testing of leaflet 2022-2024
Ticagrelor B01AC Platelet aggregation inhibitors excl. Heparin User testing of leaflet 2022-2024
Trabectedin L01CX Other plant alkaloids and natural products User testing of leaflet 2022-2024
Trastuzumab L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors User testing of leaflet 2022-2024
Trastuzumab deruxtecan L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors User testing of leaflet 2022-2024
Tremelimumab L01FX Other monoclonal antibodies User testing of leaflet 2022-2024
Fostemsavir J05AX Other antivirals User testing of leaflet 2022-2024
Cetirizine S01GX Other Antiallergics User testing of leaflet 2022-2024
Cefepime + sulbactam J01DE Fourth-generation cephalosporins User testing of leaflet 2022-2024
Ceftriaxone + Sulbactam J01DD Third-generation cephalosporins User testing of leaflet 2022-2024
Cefuroxime J01DC Second-generation cephalosporins User testing of leaflet 2022-2024
Emicizumab B02BX Other systemic hemostatics User testing of leaflet 2022-2024
Enalapril C09AA ACE inhibitors, plain User testing of leaflet 2022-2024
Ertapenem J01DH Carbapenems User testing of leaflet 2022-2024
Isotretinoin D10BA Retinoids for treatment of acne User testing of leaflet 2022-2024
Metformin + glimepiride A10BD Combinations Of Oral Blood Glucose Lowering Drugs User testing of leaflet 2022-2024
Amino Acids B05BA Solutions for parenteral nutrition User testing of leaflet 2022-2024
Hydrochlorothiazide + ramipril C09BA ACE inhibitors and diuretics User testing of leaflet 2022-2024
Apixaban B01AF Direct factor Xa inhibitors User testing of leaflet 2022-2024
Acetylsalicylic acid B01AC Platelet aggregation inhibitors excl. Heparin User testing of leaflet 2022-2024
Metamizole sodium N02BB Pyrazolones User testing of leaflet 2022-2024
Ginkgo biloba N06DX Other anti-dementia drugs User testing of leaflet 2022-2024
Hyoscine butylbromide A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds User testing of leaflet 2022-2024
Agomelatin N06AX Other antidepressants User testing of leaflet 2022-2024
Valsartan + indapamide C09DA Angiotensin II antagonists and diuretics User testing of leaflet 2022-2024
Varicella vaccine (live)) J07BK Zoster, live attenuated User testing of leaflet 2022-2024
Salbutamol R03AC Selective beta-2-adrenoreceptor agonists User testing of leaflet 2022-2024
Water for injections V07AB Solvents and Diluting Agents,Incl Irrigat Solut User testing of leaflet 2022-2024
Gadobutrol V08CA Paramagnetic contrast media User testing of leaflet 2022-2024
Obinutuzumab L01FA CD20 (Clusters of Differentiation 20) inhibitors User testing of leaflet 2022-2024
Granisetron A04AA Serotonin (5HT3) antagonists User testing of leaflet 2022-2024
Dexketoprofen M01AE Propionic acid derivatives User testing of leaflet 2022-2024
Cyproterone + ethinylestradiol G03HB Antiandrogens and estrogens User testing of leaflet 2022-2024
Cefodizime J01DD Third-Generation Cephalosporins User testing of leaflet 2022-2024
Alanyl glutamine B05XB Amino acids User testing of leaflet 2022-2024
Goserelin L02AE Gonadotropin releasing hormone analogues User testing of leaflet 2022-2024
Rabeprazole A02BC Proton pump inhibitors User testing of leaflet 2022-2024
Sebelipase alfa A16AB Enzymes User testing of leaflet 2022-2024
Lamivudine + abacavir J05AR Antivirals for treatment of HIV infections, combinations User testing of leaflet 2022-2024
Acetylsalicylic acid + clopidogrel B01AC Platelet aggregation inhibitors excl. Heparin User testing of leaflet 2022-2024
Lamotrigine N03AX Other antiepileptics User testing of leaflet 2022-2024
Levosalbutamol R03AC Selective Beta-2-Adrenoceptor Agonists User testing of leaflet 2022-2024
Glucosaminylmuramyldipeptide L03A Immunostimulating Agents User testing of leaflet 2022-2024
Losartan C09CA Angiotensin II antagonists, plain User testing of leaflet 2022-2024
Лорноксикам M01AC Oxicams User testing of leaflet 2022-2024
Pyridoxine + magnesium lactate A12CC Magnesium User testing of leaflet 2022-2024
Naproxen M01AE Propionic acid derivatives User testing of leaflet 2022-2024
Ibuprofen M01AE Propionic acid derivatives User testing of leaflet 2022-2024
Indapamide + perindopril C09BA ACE inhibitors and diuretics User testing of leaflet 2022-2024
Simoctocog alfa B02BD Blood coagulation factors User testing of leaflet 2022-2024
Benzydamine A01AD Other agents for local oral treatment User testing of leaflet 2022-2024
Paroxetine N06AB Selective serotonin reuptake inhibitors User testing of leaflet 2022-2024
Paracetamol N02BE Anilides User testing of leaflet 2022-2024
Diphtheria and tetanus adsorbed, pertussis, poliomyelitis and Haemophilus influenzae type b vaccine) J07CA Bacterial and viral vaccines, combined User testing of leaflet 2022-2024
Amlodipine + perindopril C09BB ACE inhibitors and calcium channel blockers User testing of leaflet 2022-2024
Gadoxetic acid V08CA Paramagnetic contrast media User testing of leaflet 2022-2024
Measles, mumps, rubella, and varicella vaccine J07BD Measles vaccines User testing of leaflet 2022-2024
Propofol N01AX Other general anesthetics User testing of leaflet 2022-2024
Budesonide R03BA Glucocorticoids User testing of leaflet 2022-2024
Nifuroxazide A07AX Other intestinal antiinfectives User testing of leaflet 2022-2024
Albumin B05AA Blood Substitutes And Plasma Protein Fractions User testing of leaflet 2022-2024
Zanamivir J05AH Neuraminidase inhibitors User testing of leaflet 2022-2024
Zidovudine J05AF Nucleoside and nucleotide reverse transcriptase inhibitors User testing of leaflet 2022-2024
Amlodipine + perindopril + rosuvastatin C10BX HMG CoA reductase inhibitors, other combinations User testing of leaflet 2022-2024
Rocuronium Bromide M03AC Other quaternary ammonium compounds User testing of leaflet 2022-2024
Metformin + dapagliflozin A10BD Combinations of oral blood glucose lowering drugs User testing of leaflet 2022-2024
Palivizumab J06BD Antiviral monoclonal antibodies User testing of leaflet 2022-2024
Sulfasalazine A07EC Aminosalicylic acid and similar agents User testing of leaflet 2022-2024
Telmisartan + indapamide C09DA Angiotensin II antagonists and diuretics User testing of leaflet 2022-2024
hydrochlorothiazide + telmisartan + amlodipine C09DX Angiotensin II antagonists, other combinations User testing of leaflet 2022-2024
Dolutegravir J05AJ Integrase inhibitors User testing of leaflet 2022-2024
Omeprazole A02BC Proton pump inhibitors User testing of leaflet 2022-2024
Iopromide V08AB Watersoluble, nephrotropic, low osmolar X-ray contrast media User testing of leaflet 2022-2024
Finerenone C03DA Aldosterone antagonists User testing of leaflet 2022-2024
Etoposide L01CB Podophyllotoxin derivatives User testing of leaflet 2022-2024
Hepatitis A vaccine J07BC Hepatitis vaccines User testing of leaflet 2022-2024
Eribulin L01XX Other antineoplastic agents User testing of leaflet 2022-2024
Maraviroc J05AX Other antivirals User testing of leaflet 2022-2024
Aflibercept S01LA Antineovascularisation agents User testing of leaflet 2022-2024
Esomeprazol A02BC Proton pump inhibitors User testing of leaflet 2022-2024
;Hydrochlorothiazide + enalapril C09BA ACE inhibitors and diuretics User testing of leaflet 2022-2024
Lamivudine J05AF Nucleoside and nucleotide reverse transcriptase inhibitors User testing of leaflet 2022-2024
Acetylcysteine R05CB Mucolytics User testing of leaflet 2022-2024
Ethinylestradiol + drospirenone + levomefolate calcium G03AA Progestogens and estrogens, fixed combinations User testing of leaflet 2022-2024
Cetirizine R06AE Piperazine Derivatives User testing of leaflet 2022-2024
Amlodipine C08CA Dihydropyridine Derivatives Рharmacovigilance Present
Atracurium besylate M03AC Other Quaternary Ammonium Compounds Рharmacovigilance Present
Carbamazepine N03AF Carboxamide Derivatives Рharmacovigilance Present
Celecoxib M01AH Coxibs Рharmacovigilance Present
Cisplatin L01XA Platinum Compounds Рharmacovigilance Present
Docetaxel L01CD Taxanes Рharmacovigilance Present
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Рharmacovigilance Present
Epirubicin L01DB Anthracyclines and Related Substances Рharmacovigilance Present
Ferric (III) hydroxide sacharose complex B03AC Iron, Parenteral Preparations Рharmacovigilance Present
Gemcitabine L01BC Pyrimidine Analogues Рharmacovigilance Present
Imipenem + Cilastatin J01DH Carbapenems Рharmacovigilance Present
Isoniazid J04AC Hydrazides Рharmacovigilance Present
Loratadine R06AX Other Antihistamines for systemic use Рharmacovigilance Present
Moxifloxacin J01MA Fluoroquinolones Рharmacovigilance Present
Ornidazole J01XD Imidazole Derivatives Рharmacovigilance Present
Paracetamol N02B Other Analgesics and Antipyretics Рharmacovigilance Present
Pregabalin N03AX Other Antiepileptics Рharmacovigilance Present
Pyrazinamide J04AK Other Drugs For Treatment Of Tuberculosis Рharmacovigilance Present
Temozolomide L01AX Other Alkylating Agents Рharmacovigilance Present
Ciprofloxacin J01MA Fluoroquinolones Рharmacovigilance Present
Metronidazole J01XD Imidazole Derivatives Рharmacovigilance Present
Diclofenac M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids Рharmacovigilance Present
Ivabradine C01EB Other Cardiac Preparations Рharmacovigilance Present
Famciclovir J05AB Nucleosides and nucleotides Рharmacovigilance Present
Indocyanine green V04CX Other Diagnostic Agents Рharmacovigilance Present
Sulodexide B01AB Heparin Group Рharmacovigilance Present
Anagrelide L01XX Other Antineoplastic Agents Рharmacovigilance Present
Hyoscine butylbromide A03BB Belladonna Alkaloids Semisynt,Quater Ammonium Comp Рharmacovigilance Present
Fluvoxamine N06AB Serotonin Reuptake Inhibitors Selective Рharmacovigilance Present
Cytisine N07BA Antismoking Agents Рharmacovigilance Present
Natamycin A07AA Antibiotics Рharmacovigilance Present
Paracetamol + Phenylephrine + Pheniramine + Ascorbic acid N02B Other Analgesics and Antipyretics Рharmacovigilance Present
Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, Streptococcus pneumoniae L03AX Other Immunostimulating Agents Рharmacovigilance Present
Acetylcysteine R05CB Mucolytics Рharmacovigilance Present
Ascorbic acid A11GA Ascorbic Acid, Plain Рharmacovigilance Present
Nitisinone A16AX Various Alimentary Tract and Metabolism Products Рharmacovigilance Present
Phosphazide J05AF Nucleoside reverse transcriptase inhibitors Рharmacovigilance Present
Meglumine acridonacetate L03AX Other Immunostimulating Agents Рharmacovigilance Present
Cinacalcet H05BX Other anti-parathyroid agents Рharmacovigilance Present
Dexmedetomidine N05CM Other Hypnotics and Sedatives Рharmacovigilance Present
Tigecycline J01AA Tetracyclines Рharmacovigilance Present
Teriflunomide L04AA Selective Immunosuppressive Agents Рharmacovigilance Present
Iodixanol V08A X-Ray Contrast Media, Iodinated Рharmacovigilance Present
Paricalcitol H05BX Other anti-parathyroid agents Рharmacovigilance Present
Gadopentetic acid V08CA Paramagnetic Contrast Media Рharmacovigilance Present
Gadodiamide V08CA Paramagnetic Contrast Media Рharmacovigilance Present
Dantrolene M03CA Dantrolene and Derivatives Рharmacovigilance Present
Dapagliflozin A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors Рharmacovigilance Present
Raltegravir J05AX Other Drugs For Treatment Of Tuberculosis Рharmacovigilance Present
Etravirin J05AG Ненуклеозиды - ингибиторы обратной транскриптазы Рharmacovigilance Present
Clofaziminum J04BA Drugs For Treatment Of Lepra Рharmacovigilance Present
Apixaban B01AF Other Antithrombotic Agents Рharmacovigilance Present
Rivaroxaban B01AF Direct factor Xa inhibitors Рharmacovigilance Present
Eribulin L01XX Other Antineoplastic Agents Рharmacovigilance Present
Cabazitaxel L01CD Taxanes Рharmacovigilance Present
Eltrombopag B02BX Other systemic hemostatics Рharmacovigilance Present
Dabigatrani etexilas B01AA Vitamin K Antagonists Рharmacovigilance Present
Cefoperazone + Sulbactam J01DD Third-generation cephalosporins Рharmacovigilance Present
Meropenem J01DH Carbapenems Рharmacovigilance Present
Ampicillin + Sulbactam J01CR Comb Of Penicillins, Incl. Beta-Lactamase Inhib. Рharmacovigilance Present
Amoxicillin + Sulbactam J01CG Beta-Lactamase Inhibitors Рharmacovigilance Present
Ceftriaxone + Sulbactam J01DD Third-generation cephalosporins Рharmacovigilance Present
Cefuroxime J01RA Combinations Of Antibacterials Рharmacovigilance Present
Piperacillin + Tazobactam J01CR Piperacillin and Enzyme Inhibitor Рharmacovigilance Present
Biapenem J01DD Third-generation cephalosporins Рharmacovigilance Present
Sulbactam J01DD Third-generation cephalosporins Рharmacovigilance Present
Diacerein M01AX Other Antiinfl./Antirheumatic Agents, Non-Steroids Рharmacovigilance Present
Polymyxin B J01XB Polymyxins Рharmacovigilance Present
Ornidazole + Ciprofloxacin J01RA Combinations Of Antibacterials Рharmacovigilance Present
Alfacalcidol A11CC Vitamin D and Analogues Рharmacovigilance Present
Glucosamine + Chondroitin sulfate Potassium Adipate + Vitamin E M09AX Other Drugs For Disord. Of The Musc.-Skeletal Syst Рharmacovigilance Present
Nimesulide M01AX Other Antiinfl./Antirheumatic Agents, Non-Steroids Рharmacovigilance Present
Сiclosporin L04AD Calcineurin inhibitors Рharmacovigilance Present
Dextromethorphanum+ Paracetamolum + Phenylephrinum+ Chlorphenaminum N02BE ;Anilides Рharmacovigilance Present
Cycloserine J04A Drugs For Treatment Of Tuberculosis Рharmacovigilance Present
Mycophenolate mofetil L04AA Selective Immunosuppressive Agents Рharmacovigilance Present
Lactulose A06AX Other Laxatives Рharmacovigilance Present
Ketorolac M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids Рharmacovigilance Present
Levofloxacin J01MA Fluoroquinolones Рharmacovigilance Present
Tizanidine M03BX Other Centrally Acting Agents Рharmacovigilance Present
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Рharmacovigilance Present
Aminosalicylic acid J04AA Aminosalicylic Acid and Derivatives Рharmacovigilance Present
Acetylsalicylic acid+Ascorbic acid N02BA Salicylic Acid and Derivatives Рharmacovigilance Present
Micafungin J02AX Other Antimycotics for systemic use Рharmacovigilance Present
Fondaparinux sodium B01AX ;Other Antithrombotic Agents Рharmacovigilance Present
Cefepime + Sulbactam J01DE Fourth-generation cephalosporins Рharmacovigilance Present
Dimetinden R06A Antihistamines for systemic use Рharmacovigilance Present
Fluconazole J02AC Triazole Derivatives Рharmacovigilance Present
Combined herb drug A01AD Other Agents For Local Oral Treatment Phase III CT Present
Levocetirizine R06AE Piperazine Derivatives Рharmacovigilance Present
Alverine + Simeticone A03AX Other Synthetic Anticholinergic Agents Bioequivalence CT Present
Tibolone G03CX Other estrogens Marketing Authorization 2022-2024
Ertapenem J01DH Carbapenems Marketing Authorization 2022-2024
Ceftriaxone + Sulbactam J01DD Third-generation cephalosporins Marketing Authorization 2022-2024
Erlotinib L01XE Protein kinase inhibitors Marketing Authorization 2022-2024
Paliperidone N05AX ;Other Antipsychotics Marketing Authorization 2022-2024
Piperacillin + Tazobactam J01CR Piperacillin and Enzyme Inhibitor Marketing Authorization 2022-2024
Sulbactam J01DD Third-generation cephalosporins Marketing Authorization 2022-2024
Lansoprazole A02BD Other Drugs For Treatment Of Peptic Ulcer Marketing Authorization 2022-2024
Fat Emulsions For Parenteral Nutrition B05BA Solutions For Parenteral Nutrition Marketing Authorization 2022-2024
Vancomycin J01XA Glycopeptide Antibacterials Marketing Authorization 2022-2024
Salbutamol R03AC Selective beta-2-adrenoreceptor agonists Marketing Authorization 2022-2024
Apixaban B01AF Other Antithrombotic Agents Marketing Authorization 2022-2024
Gadopentetic acid V08CA Paramagnetic Contrast Media Marketing Authorization 2022-2024
Cabazitaxel L01CD Taxanes Marketing Authorization 2022-2024
Piperacillin + Tazobactam J01CR Piperacillin and Enzyme Inhibitor Bringing dossier into the EEU complience 2022-2024
Cefoperazone+Sulbactam J01DD Third-generation cephalosporins Bringing dossier into the EEU complience 2022-2024
Ticagrelor B01AC Platelet aggregation inhibitors excl. Heparin Bioequivalence CT Present
Diacerein M01AX Other Antiinfl./Antirheumatic Agents, Non-Steroids Bioequivalence CT Present
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Bioequivalence CT Present
Dolutegravir+Rilpivirine J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT Present
Glecaprevir+Pibrentasvir J05AP Antivirals For Treatment Of Hcv Infections Bioequivalence CT Present
Elbasvir+Grazoprevir J05AP Antivirals For Treatment Of Hcv Infections Bioequivalence CT Present
Dolutegravir+Lamivudine J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT Present
Rivaroxaban B01AF Direct factor Xa inhibitors Bioequivalence CT Present
Apixaban B01AF Direct factor Xa inhibitors Bioequivalence CT Present
Aminoacids for parenteral nutrition A16AA Amino Acids and Derivatives Bringing dossier into the EEU complience Present
Ataluren M09AX Other Drugs For Disord. Of The Musc.-Skeletal Syst Bringing dossier into the EEU complience Present
Valaciclovir J05AB Nucleosides and nucleotides Bringing dossier into the EEU complience Present
Ibuprofen M01AE Propionic Acid Derivatives Bringing dossier into the EEU complience Present
Moxifloxacin J01MA Fluoroquinolones Bringing dossier into the EEU complience Present
Ornidazole + Ciprofloxacin J01RA Combinations Of Antibacterials Bringing dossier into the EEU complience Present
Amino Acids,Incl Combinations With Polypeptides V06DD Amino Acids,Incl Combinations With Polypeptides Bringing dossier into the EEU complience Present
Granisetron A04A Other Antiemetics Marketing Authorization Present
Cisatracurium besilate M03AC Other Quaternary Ammonium Compounds Marketing Authorization Present
Cinacalcet H05BX Other anti-parathyroid agents Bringing dossier into the EEU complience Present
Сiclosporin L04AD Calcineurin inhibitors Bringing dossier into the EEU complience Present
Meropenem J01DH Carbapenems Bringing dossier into the EEU complience Present
Ceftazidimum + Avibactamum J01D Other Beta-Lactam Antibacterials Bringing dossier into the EEU complience Present
Cefodizimum J01DD Third-generation cephalosporins Bringing dossier into the EEU complience Present
Blood Coagulation Factors B02B Vitamin K and Other Hemostatics Bringing dossier into the EEU complience Present
Sulbactam J01DD Third-generation cephalosporins Marketing Authorization Present
Peritoneal Dialytics B05CX Other Irrigating Solutions Bringing dossier into the EEU complience Present
Meropenem J01DH Carbapenems Marketing Authorization Present
Meglumine acridonacetate L03AX Other Immunostimulating Agents Bringing dossier into the EEU complience Present
Levocetirizine R06AE Piperazine Derivatives Bringing dossier into the EEU complience Present
Fat Emulsions For Parenteral Nutrition B05BA Solutions For Parenteral Nutrition Bringing dossier into the EEU complience Present
Dextromethorphan + Paracetamol + Phenylephrine + Chlorphenamine N07XX Anilides Bringing dossier into the EEU complience Present
Dapagliflozin A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors Bringing dossier into the EEU complience Present
Lactulose A06AD Osmotically acting laxatives Bringing dossier into the EEU complience Present
Glucoseminylmuramildipeptidum L03AX Other Immunostimulating Agents User testing of leaflet Present
Baloxavir marboxil J05AX Other Drugs For Treatment Of Tuberculosis User testing of leaflet Present
Coffeinum + Paracetamolum + Phenylephrinum + Chlorphenaminum N02B ;Anilides User testing of leaflet Present
Aminoacids for parenteral nutrition A16AA Amino Acids and Derivatives User testing of leaflet Present
Simoctocog alfa B2BD Blood Coagulation Factors User testing of leaflet Present
Сolistimethate sodium J1XB Polymyxins User testing of leaflet Present
Mercaptamine A16AA Amino Acids and Derivatives User testing of leaflet Present
Dorzolamide S1EC Carbonic Anhydrase Inhibitors User testing of leaflet Present
Perampanel N3A Other Antiepileptics User testing of leaflet Present
Cefoperazone+Sulbactam J01DD Third-generation cephalosporins User testing of leaflet Present
Rekombinantnyi albumin B05AA Blood Substitutes And Plasma Protein Fractions User testing of leaflet Present
Glucoseminyl muramildipeptide L3AX Other Immunostimulating Agents User testing of leaflet Present
Аmorolfine D1AE ;Other Antifungals for topical use User testing of leaflet Present
Metformin + glimepiride A10BD Combinations Of Oral Blood Glucose Lowering Drugs User testing of leaflet Present
Fat Emulsions For Parenteral Nutrition B05BA Solutions For Parenteral Nutrition User testing of leaflet Present
Nilotinib L1XE Protein kinase inhibitors User testing of leaflet Present
Glofitamab L01X Other Antineoplastic Agents User testing of leaflet Present
Ticagrelor B1AC Platelet Aggregation Inhibitors Excl. Heparin User testing of leaflet Present
Lapatinib L1XE Protein kinase inhibitors User testing of leaflet Present
Carboplatin L1XA Platinum Compounds User testing of leaflet Present
Darolutamide L02B Hormone Antagonists and Related Agents User testing of leaflet Present
Diclofenac M1A Antiinflammatory/Antirheumatic Prod.,Non-Steroids User testing of leaflet Present
Riamilovir J05AX Other Antivirals User testing of leaflet Present
Cefodizimum J1DD Third-generation cephalosporins User testing of leaflet Present
Dapagliflozin A1BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors User testing of leaflet Present
Acetylsalicylic acid + clopidogrel B01AC Platelet aggregation inhibitors excl. Heparin User testing of leaflet Present
Immunostimulator L03AX Other Immunostimulating Agents User testing of leaflet Present
Fostemsavir J5AX Other antivirals User testing of leaflet Present
Vancomycin J1XA Glycopeptide Antibacterials User testing of leaflet Present
Trastuzumab L1XC Monoclonal antibodies User testing of leaflet Present
Vilanterol, umeclidinium bromide and fluticasone furoate R3AL Adrenergics in combination with anticholinergics User testing of leaflet Present
Sevoflurane N01A Anesthetics, General User testing of leaflet Present
Latanoprost S1EE Prostaglandin analogues User testing of leaflet Present
Iohexol V8AB Watersol.,Nephrotropic, Low Osm. X-Ray Contr.Media User testing of leaflet Present
Atezolizumab L1FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors User testing of leaflet Present
Atorvastatin C1AA HMG CoA Reductase Inhibitors User testing of leaflet Present
;Hydrochlorothiazide + enalapril C9BA ACE inhibitors and diuretics User testing of leaflet Present
Dolutegravir + Rilpivirine J5AR Antivirals for treatment of HIV infections, combination User testing of leaflet Present
Adapalene D1AD Retinoids for topical use in acne User testing of leaflet Present
Enalapril C9AA ACE inhibitors, plain User testing of leaflet Present
Pazufloxacin J1MA Fluoroquinolones User testing of leaflet Present
Insulin glargine A1AE Insulins and analogues, long-acting User testing of leaflet Present
Rosuvastatin C1AA HMG CoA Reductase Inhibitors User testing of leaflet Present
Selumetinib L1EE Mitogen-activated protein kinase (MEK) inhibitors User testing of leaflet Present
Tremelimumab L1FX Other monoclonal antibodies User testing of leaflet Present
Amoxicillin+Clavulanic acid J1CR Amoxicillin and Enzyme Inhibitor User testing of leaflet Present
Ravulizumab L4AA Selective immunosuppressants User testing of leaflet Present
Rivaroxaban B1AF Direct factor Xa inhibitors User testing of leaflet Present
Caspofungin J2AX Other antimycotics for systemic use User testing of leaflet Present
Moxifloxacin J1MA Fluoroquinolones User testing of leaflet Present
Ocrelizumab L4AA Selective immunosuppressants User testing of leaflet Present
Fish Oil A11C Vitamin D and Analogues User testing of leaflet Present
Paracetamol + Phenylephrine + Pheniramine N02BE Anilides User testing of leaflet Present
Paracetamol + Phenylephrine + Pheniramine + Ascorbic acid N02B Other Analgesics and Antipyretics User testing of leaflet Present
Indapamid + Perindopril + Rosuvastatin C1BX HMG CoA reductase inhibitors, other combinations User testing of leaflet Present
Amlodipinum + Indapamidum + Perindoprilum C9BX Ингибиторы АПФ, другие комбинации User testing of leaflet Present
Ibuprofen, Combinations M1AE Propionic acid derivatives User testing of leaflet Present
Multivitamins, Plain A11BA Multivitamins, Plain User testing of leaflet Present
Capivasertib L1EX Other protein kinase inhibitors User testing of leaflet Present
Levonorgestrel G3AC 3-Oxoandrosten (4) Derivatives User testing of leaflet Present
Ertapenem J1DH Carbapenems User testing of leaflet Present
Gemcitabine L1BC Pyrimidine Analogues User testing of leaflet Present
Xylometazoline R1AA Sympathomimetics, Plain User testing of leaflet Present
Norelgestromin + ethinylestradiol G3AA Progestogens and estrogens, fixed combinations User testing of leaflet Present
Lansoprazole A2BD Other Drugs For Treatment Of Peptic Ulcer User testing of leaflet Present
Tetryzoline S01GA Sympathomimetics Used As Decongestants User testing of leaflet Present
Amiodarone C1BD Antiarrhythmics, Class III User testing of leaflet Present
;Dexpanthenol D3AX Other cicatrizants User testing of leaflet Present
Dimenhydrinate R6AA Aminoalkyl ethers User testing of leaflet Present
Metoprolol C7AB Beta blocking agents, selective User testing of leaflet Present
Belimumab L4AA Selective Immunosuppressive Agents User testing of leaflet Present
Pertuzumab and trastuzumab L1XY Combinations of antineoplastic agents User testing of leaflet Present
Carfilzomib L1XG Proteasome inhibitors User testing of leaflet Present
Cefuroxime J1RA Combinations Of Antibacterials User testing of leaflet Present
Danicopan L4AJ Selective Immunosuppressive Agents User testing of leaflet Present
Herbal drug A03AX Other Synthetic Anticholinergic Agents User testing of leaflet Present
Olaparib L1XK Poly (ADP-ribose) polymerase (PARP) inhibitors User testing of leaflet Present
Ivacaftor, tezacaftor and elexacaftor R7AX Other respiratory system products User testing of leaflet Present
Acalabrutinib L1EL Bruton`s tyrosine kinase (BTK) inhibitors User testing of leaflet Present
Piperacillin + Tazobactam J01CR Piperacillin and Enzyme Inhibitor User testing of leaflet Present
Valproate sodium + Valproic acid N03AG Fatty acid derivatives User testing of leaflet Present
Telmisartan C9CA Angiotensin II Antagonists, Plain User testing of leaflet Present
Emicizumab B02BX Other systemic hemostatics User testing of leaflet Present
Vildagliptin A1BH Dipeptidyl peptidase 4 (DPP-4) inhibitors User testing of leaflet Present
Dienogest + Ethinylestradiol G03AA Progestogens and estrogens, fixed combinations User testing of leaflet Present
Tezepelumab R3DX Other systemic drugs for obstructive airway diseases User testing of leaflet Present
Aceclofenac M1AB Acetic Acid Derivatives and Related Substances User testing of leaflet Present
Gestodene and Estrogen G03AA Progestogens and estrogens, fixed combinations User testing of leaflet Present
Ademetionine A16AA Amino acids and derivatives User testing of leaflet Present
Rituximab L1FA CD2 (Clusters of Differentiation 2) inhibitors User testing of leaflet Present
Gadopentetate dimeglumine V08C Agnetic Resonance Imaging Contrast Media User testing of leaflet Present
Mosunetuzumab L1FX Other monoclonal antibodies User testing of leaflet Present
Trastuzumab deruxtecan L1FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors User testing of leaflet Present
Pertuzumab L1FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors User testing of leaflet Present
Cetirizine R6AE Piperazine Derivatives User testing of leaflet Present
Levofloxacin J1MA Fluoroquinolones User testing of leaflet Present
Dienogest + Ethinylestradiol G03AA Progestogens and estrogens, fixed combinations User testing of leaflet Present
Valsartan, Amlodipine and Hydrochlorothiazide C9DX Angiotensin II antagonists, other combinations User testing of leaflet Present
Diosmin + Hesperidin C05CA Bioflavonoids User testing of leaflet Present
Testosterone G03BA 3-Oxoandrosten (4) Derivatives User testing of leaflet Present
Drospirenone + Ethinylestradiol G3AA Progestogens and estrogens, fixed combinations User testing of leaflet Present
Lidocaine + Phenazone S02D Other Otologicals User testing of leaflet Present
Metformin and vildagliptin A1BD Combinations Of Oral Blood Glucose Lowering Drugs User testing of leaflet Present
Moxifloxacin J1MA Fluoroquinolones User testing of leaflet Present
Cabazitaxel L1CD Taxanes User testing of leaflet Present
Insulin glulisine A1AB Insulins and analogues for injection, fast-acting User testing of leaflet Present
Asfotase alfa A16AB Enzymes User testing of leaflet Present
Dienogest + Ethinylestradiol G03FA Progestogens and Estrogens, Fixed Combinations User testing of leaflet Present
Ambroxol R5CB Mucolytics User testing of leaflet Present
Telmisartan and Amlodipine C9DB Angiotensin II antagonists and calcium channel blockers User testing of leaflet Present
Busulfan L1AB Alkyl Sulphonates User testing of leaflet Present
Valproic acid N3AG Fatty Acid Derivatives User testing of leaflet Present
Valsartan C9CA Angiotensin II Antagonists, Plain User testing of leaflet Present
Valsartan + Hydrochlorothiazide C9DA Angiotensin II Antagonists and Diuretics User testing of leaflet Present
Trabectedin L1CX Other plant alkaloids and natural products User testing of leaflet Present
Drospirenonum + Aethinyloestradiolum + Calcii levomefolas C09D Angiotensin II Antagonists, Combinations User testing of leaflet Present
Ivacaftor, tezacaftor and elexacaftor R7AX Other respiratory system products User testing of leaflet Present
Hydrochlorothiazidum + Telmisartan C9DA Angiotensin II Antagonists and Diuretics User testing of leaflet Present
Clindamycin D1AF Antiinfectives for treatment of acne User testing of leaflet Present
Fish Oil A11C Vitamin D and Analogues User testing of leaflet Present
Pantoprazole A2BC Proton Pump Inhibitors User testing of leaflet Present
Vaccine for the prevention of diphtheria and tetanus, adsorbed, acellular whooping cough, inactivated polio J07C Bacterial and Viral Vaccines, Combined User testing of leaflet Present
Metronidazole J1XD Imidazole Derivatives User testing of leaflet Present
Combined herb drug A01AD Other Agents For Local Oral Treatment User testing of leaflet Present
Herbal drug A03AX Other Synthetic Anticholinergic Agents User testing of leaflet Present
Multivitamins, Plain A11BA Multivitamins, Plain User testing of leaflet Present
Dabigatrani etexilas B1AA Vitamin K Antagonists User testing of leaflet Present
Mometasone D7AC Corticosteroids, Potent (Group III) User testing of leaflet Present
Amlodipine + perindopril C09BB ACE inhibitors and calcium channel blockers User testing of leaflet Present
Rivaroxaban B1AF Direct factor Xa inhibitors User testing of leaflet Present
Ipratropium bromide + xylometazoline R01AB Sympathomimetics, combinations excl. Corticosteroids User testing of leaflet Present
Amlodipine + perindopril C09BB ACE inhibitors and calcium channel blockers User testing of leaflet Present
Anifrolumab L1FX Прочие моноклональные антитела User testing of leaflet Present
Acetylcysteine R5CB Mucolytics User testing of leaflet Present
Tranexamic acid B02AA Аминокислоты User testing of leaflet Present
Polatuzumab vedotin B01AC Platelet Aggregation Inhibitors Excl. Heparin User testing of leaflet Present
Colecalciferol A11CC Vitamin D And Analogues User testing of leaflet Present
Acetylsalicylic acid B1AC Platelet aggregation inhibitors excl. Heparin User testing of leaflet Present
Hydrochlorothiazide + losartan C09DA Angiotensin II Antagonists And Diuretics User testing of leaflet Present
Eribulin L1XX Other antineoplastic agents User testing of leaflet Present
Lornoxicam M01A Antiinflammatory And Antirheumatic Products User testing of leaflet Present
Amlodipine + perindopril C09BB ACE inhibitors and calcium channel blockers User testing of leaflet Present
Mesna V03A All Other Therapeutic Products User testing of leaflet Present
Melphalan L1AA Nitrogen Mustard Analogues User testing of leaflet Present
Sulbactam J1DD Third-generation cephalosporins User testing of leaflet Present
Budesonidum + Formoterolum R03AA Alpha- and Beta-adrenoreceptor agonists User testing of leaflet Present
Etoposide L1CB Podophyllotoxin Derivatives User testing of leaflet Present
Herbal drug A03AX Other Synthetic Anticholinergic Agents User testing of leaflet Present
Coffeinum + Paracetamolum + Phenylephrinum + Chlorphenaminum N02B ;Anilides User testing of leaflet Present
Tibolone G3CX Other estrogens User testing of leaflet Present
Desloratadine R6AX Other Antihistamines for systemic use User testing of leaflet Present
Phosaprepitant A04AD Other Antiemetics User testing of leaflet Present
Gadoxetic acid V8CA Paramagnetic contrast media User testing of leaflet Present
Etoricoxib M1AH Coxibs User testing of leaflet Present
Xylometazoline R1AA Sympathomimetics, Plain User testing of leaflet Present
Sertaconazole D01AС Imidazole And Triazole Derivatives User testing of leaflet Present
Ibuprofen M1AE Propionic Acid Derivatives User testing of leaflet Present
Epoetin alfa B03XA Other Antianemic Preparations User testing of leaflet Present
Patiromer V3AE Drugs For Treatment Of Hyperkalemia And Hyperphosphatemia User testing of leaflet Present
Budesonidum + Glycopyrronii bromidum + Formoterolum R03AA Alpha- and Beta-adrenoreceptor agonists User testing of leaflet Present
hydrochlorothiazide + telmisartan + amlodipine C09DX Angiotensin II antagonists, other combinations User testing of leaflet Present
Fat Emulsions For Parenteral Nutrition B05BA Solutions For Parenteral Nutrition User testing of leaflet Present
Sodium picosulfate A06AB Contact Laxatives User testing of leaflet Present
Telmisartan + indapamide C09DA Angiotensin II antagonists and diuretics User testing of leaflet Present
Magnesium + Pyridoxinum A11HA Other plain vitamin preparations User testing of leaflet Present
Valsartan + Indapamide C9DA Angiotensin II Antagonists and Diuretics User testing of leaflet Present
Finerenone C03DA Aldosterone antagonists User testing of leaflet Present
Aminoacids for parenteral nutrition + Other medicines [Fat emulsions + Dextrose + Multimineral] B05BA Solutions for parenteral nutrition User testing of leaflet Present
Hydrochlorothiazide C03AA Thiazides, Plain User testing of leaflet Present
Alglucosidase alfa A16AB Enzymes User testing of leaflet Present
Amoxicillin + Sulbactam J01CG Beta-Lactamase Inhibitors User testing of leaflet Present
Tenoxicam M01AC Oxicams User testing of leaflet Present
Trastuzumab emtansine L1FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors User testing of leaflet Present
Vaccine for the prevention of diphtheria and tetanus, adsorbed, acellular whooping cough, inactivated polio J07C Bacterial and Viral Vaccines, Combined User testing of leaflet Present
Fosfomycin J1XX Other Antibacterials User testing of leaflet Present
Herbal drug A03AX Other Synthetic Anticholinergic Agents User testing of leaflet Present
Moxonidine C2AC Imidazoline Receptor Agonists User testing of leaflet Present
Apixaban B1AF Other Antithrombotic Agents User testing of leaflet Present
Clotrimazole D1A Antifungals for topical use User testing of leaflet Present
Benzoyl peroxide + Сlindamycin D1AF Antiinfectives For Treatment Of Acne User testing of leaflet Present
Drotaverine A03AD Papaverine and Derivatives User testing of leaflet Present
Safinamid N4BD N4BD User testing of leaflet Present
Faricimab L1XC Monoclonal antibodies User testing of leaflet Present
Biapenem J1DD Third-generation cephalosporins User testing of leaflet Present
Imiquimod D6BB Antivirals User testing of leaflet Present
Salbutamol R3AC Selective beta-2-adrenoreceptor agonists User testing of leaflet Present
Vericiguat C1DA Organic nitrates User testing of leaflet Present
Cefoperazone+Sulbactam J01DD Third-generation cephalosporins User testing of leaflet Present
Vismodegib L1XJ Hedgehog pathway inhibitors User testing of leaflet Present
Laronidase A16AB Enzymes User testing of leaflet Present
Lozartan C9CA Angiotensin II Antagonists, Plain User testing of leaflet Present
Glimepiride A10BB ;Sulfonamides, Urea Derivatives User testing of leaflet Present
Doxylamine hydrosuccinas R6AA Aminoalkyl Ethers User testing of leaflet Present
Ambroxolum + Guaifenesinum + Levosalbutamolum R07A Other respiratory system products User testing of leaflet Present
Trientine A16AX Various Alimentary Tract and Metabolism Products User testing of leaflet Present
Vaccine for the prevention of meningococcal infections J07AH Meningococcal Vaccines User testing of leaflet Present
Satralizumab L4AC Interleukin inhibitors User testing of leaflet Present
Entrectinib L1XE Protein kinase inhibitors User testing of leaflet Present
Ceftriaxone + Sulbactam J1DD Third-generation cephalosporins User testing of leaflet Present
Loteptednolum S01BA Corticosteroids Plain User testing of leaflet Present
Cenegermin S01XA Other Ophthalmologicals User testing of leaflet Present
Mometasone D7AC Corticosteroids, Potent (Group III) User testing of leaflet Present
Obinutuzumab L1FA ;CD2 (Clusters of Differentiation 2) inhibitors User testing of leaflet Present
Heparinum natrium + Dexpanthenolum + Dimethylsulfoxydum B1AX ;Other Antithrombotic Agents User testing of leaflet Present
Paclitaxel L1CD Taxanes User testing of leaflet Present
Ceftriaxone J01DD Third-generation cephalosporins User testing of leaflet Present
Ceftazidimum J01DD Third-generation cephalosporins User testing of leaflet Present
Naproxen M1AE Propionic Acid Derivatives User testing of leaflet Present
Cidofovir J5AB Nucleosides and nucleotides User testing of leaflet Present
Tacrolimus L4AD Calcineurin inhibitors User testing of leaflet Present
Herbal drug A03AX Other Synthetic Anticholinergic Agents User testing of leaflet Present
Lysocime + Pyridoxine R02AA Antiseptics User testing of leaflet Present
Trimebutine A03AA Synt Anticholin,Esters With Tertiary Amino Group User testing of leaflet Present
Torasemide C3CA Sulfonamides, Plain User testing of leaflet Present
Insulin A10AB Insulins and analogues for injection, fast-acting User testing of leaflet Present
Ipidacrine N06DA Anticholinesterases User testing of leaflet Present
Ibuprofen + Paracetamol M01AE Propionic Acid Derivatives User testing of leaflet Present
Bosentan C2KX Antihypertensives for pulmonary arterial hypertension User testing of leaflet Present
Zinc sulfate A12CB ;Zincum User testing of leaflet Present
Cemiplimab L01XC Monoclonal antibodies User testing of leaflet Present
Riociguat С02KX Antihypertensives for pulmonary arterial hypertension User testing of leaflet Present
Fludarabine L1BB Purine analogues User testing of leaflet Present
Oseltamivir J5AH Combinations Of Antibacterials User testing of leaflet Present
Dienogest G3FA Progestogens and Estrogens, Fixed Combinations User testing of leaflet Present
Tigecycline J1AA Tetracyclines User testing of leaflet Present
Dimetinden R6A Antihistamines for systemic use User testing of leaflet Present
Dexketoprofen M1AE Propionic Acid Derivatives User testing of leaflet Present
Amlodipinum + Perindoprilum + Rosuvastatinum C1BX HMG CoA reductase inhibitors, other combinations User testing of leaflet Present
Fondaparinux sodium B1AX ;Other Antithrombotic Agents User testing of leaflet Present
Valproate sodium N03AG Fatty Acid Derivatives User testing of leaflet Present
Metformin + Sitagliptin A10BD Combinations Of Oral Blood Glucose Lowering Drugs User testing of leaflet Present
Cobimetinib L01XE Protein kinase inhibitors User testing of leaflet Present
Herbal drug A03AX Other Synthetic Anticholinergic Agents User testing of leaflet Present
Herbal drug A03AX Other Synthetic Anticholinergic Agents User testing of leaflet Present
Plerixafor L03AX Other Immunostimulating Agents User testing of leaflet Present
Glycopyrronii bromidum H2AB Glucocorticoids User testing of leaflet Present
Sitagliptin A1BH Dipeptidyl peptidase 4 (DPP-4) inhibitors User testing of leaflet Present
Salmeterolum+ Fluticasonum R3AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergicsAdrenergics in combination with corticosteroids or other drugs, excl. Anticholinergics User testing of leaflet Present
Herbal drug A03AX Other Synthetic Anticholinergic Agents User testing of leaflet Present
Adalimumab L4AB Tumor necrosis factor alpha (TNFα) inhibitors User testing of leaflet Present
Levodopa + Karbidopa + Entakapon N04BA Dopa and dopa derivatives User testing of leaflet Present
Herbal drug A03AX Other Synthetic Anticholinergic Agents User testing of leaflet Present
Bromhexine + Guaifenesin + Salbutamol R05C EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS User testing of leaflet Present
Herbal drug A03AX Other Synthetic Anticholinergic Agents User testing of leaflet Present
Vemurafenib L01XE Protein kinase inhibitors User testing of leaflet Present
Sildenafil G4BE Drugs used in erectile dysfunction User testing of leaflet Present
Abiraterone L02BX Other hormone antagonists and related agents User testing of leaflet Present
Benzyldimethyl-myristoilamin-propylammonium D08AJ Quaternary Ammonium Compounds User testing of leaflet Present
Сitric acid + Potassium bicarbonate + Sodium citrate G04BC Urinary Concrement Solvents User testing of leaflet Present
Viral Vaccines J07BX Other Viral Vaccines User testing of leaflet Present
Glycopyrronii bromidum + Indacaterolum H02AB Glucocorticoids User testing of leaflet Present
Alirocumab C1AX Other Cholesterol and Triglyceride Reducers User testing of leaflet Present
Aducanumab N6DX Other anti-dementia drugs User testing of leaflet Present
Finerenone C03DA Aldosterone Antagonists User testing of leaflet Present
Faricimab L1XC Monoclonal antibodies User testing of leaflet Present
Alectinib L1XE Protein kinase inhibitors User testing of leaflet Present
Peginterferon alfa-2b L03AB Interferons User testing of leaflet Present
Herbal drug A03AX Other Synthetic Anticholinergic Agents User testing of leaflet Present
Lenalidomide L4AX Other Immunosuppressive Agents User testing of leaflet Present
Metronidazole + Chlorhexidine A01AB Antiinfectives For Local Oral Treatment User testing of leaflet Present
Regorafenib L1XE Protein kinase inhibitors User testing of leaflet Present
Vardenafil G04BE Drugs used in erectile dysfunction User testing of leaflet Present
Sorafenib L1XE Protein kinase inhibitors User testing of leaflet Present
immunoglobulin L04AA Selective Immunosuppressive Agents User testing of leaflet Present
Acetylsalicylic acid + clopidogrel B01AC Platelet aggregation inhibitors excl. Heparin User testing of leaflet Present
Nimesulide M1AX Other Antiinfl./Antirheumatic Agents, Non-Steroids User testing of leaflet Present
Lenvatinib L1XE Ингибиторы протеинкиназы User testing of leaflet Present
Ciprofloxacin J1MA Fluoroquinolones User testing of leaflet Present
Azithromycin J1FA Macrolides User testing of leaflet Present
Nifedipine C8CA Dihydropyridine Derivatives User testing of leaflet Present
Carvedilol C7AG Alpha and Beta Blocking Agents User testing of leaflet Present
Fulvestrant L2BA Anti-Estrogens User testing of leaflet Present
Aluminii hydroxidum-Magnesii carbonas + Magnesii hydroxidum A02AX  Antacids User testing of leaflet Present
Viral Vaccines J07BX Other Viral Vaccines User testing of leaflet Present
Herbal drug A03AX Other Synthetic Anticholinergic Agents User testing of leaflet Present
Influenza Vaccines J07B Influenza Vaccines User testing of leaflet Present
Rosuvastatin + Valsartan C10BX HMG CoA reductase inhibitors, other combinations User testing of leaflet Present
Telmisartan and Amlodipine C9DB Angiotensin II antagonists and calcium channel blockers User testing of leaflet Present
Darunavir J5AE HIV-proteinase inhibitors User testing of leaflet Present
Insulin A10AB Insulins and analogues for injection, fast-acting User testing of leaflet Present
Mycophenolate mofetil L4AA Selective Immunosuppressive Agents User testing of leaflet Present
Decitabine L1BC Pyrimidine Analogues User testing of leaflet Present
Cyproterone G3HA Antiandrogens, Plain Preparations User testing of leaflet Present
Mycophenolic acid L4AA Selective Immunosuppressive Agents User testing of leaflet Present
Abacavir J5AF Nucleoside reverse transcriptase inhibitors User testing of leaflet Present
Oxaliplatin L1XA Platinum Compounds User testing of leaflet Present
Bortezomib L1XX Other Antineoplastic Agents User testing of leaflet Present
Alglucosidase alfa A16AB Enzymes User testing of leaflet Present

CONTACTS

Russia, Moscow.

Multifanctional complex «Federation»
Presnenskaya embankment, 12
East Tower, 27th floor, 17 room.

© ARS PHARMRUSSIA: CLINICAL & REGULATORY EXPERT CRO, 2009-2024
All rights reserved.